TuHURA Biosciences (HURA) 10-K 28 Sep 21 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2021	Sep. 28, 2021	Dec. 31, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Trading Symbol	KTRA
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Registrant Name	Kintara Therapeutics, Inc.
Entity Central Index Key	0001498382
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 26.9
Entity Common Stock, Shares Outstanding		43,174,989
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Incorporation, State or Country Code	NV
Entity File Number	001-37823
Entity Tax Identification Number	99-0360497
Entity Address, Address Line One	12707 High Bluff Dr
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92130
City Area Code	858
Local Phone Number	350-4364
Document Annual Report	true
Document Transition Report	false
Documents Incorporated by Reference	None

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020
Current assets
Cash and cash equivalents	$ 10,537	$ 2,392
Prepaid expenses, deposits and other	756	365
Clinical trial deposit	500
Deferred loan costs		94
Total current assets	11,793	2,851
Clinical trial deposit	1,600
Property, equipment and intangibles - net	150	2
Deferred financing costs		85
Total assets	13,543	2,938
Current liabilities
Accounts payable and accrued liabilities	2,219	2,011
Related party payables	561	664
Total current liabilities	2,780	2,675
Milestone payment liability	182
Total liabilities	2,962	2,675
Stockholders’ equity
Common stock Authorized 175,000 shares at June 30, 2021 (June 30, 2020 - 95,000) $0.001 par value 32,740 issued at June 30, 2021 (June 30, 2020 – 11,458)	33	11
Additional paid-in capital	106,821	65,148
Accumulated deficit	(111,225)	(69,721)
Accumulated other comprehensive income	21	21
Total stockholders’ equity	10,581	263
Total liabilities and stockholders’ equity	13,543	2,938
Preferred Stock Series A
Stockholders’ equity
Preferred stock	279	279
Preferred Stock Series B
Stockholders’ equity
Preferred stock		4,525
Total stockholders’ equity		$ 4,525
Preferred Stock Series C
Stockholders’ equity
Preferred stock	$ 14,652

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Jun. 30, 2020
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	175,000,000	95,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	32,740,000	11,458,000
Preferred Stock Series A
Preferred Stock, shares issued	279,000	279,000
Preferred stock, shares outstanding	279,000	279,000
Preferred Stock Series B
Preferred Stock, shares issued	0	649,000
Preferred stock, shares outstanding	0	649,000
Preferred Stock Series C
Preferred Stock, shares issued	20,000	0
Preferred stock, shares outstanding	20,000	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Expenses
Research and development	$ 11,815	$ 3,630
General and administrative	9,757	4,514
Merger costs	500	1,054
In-process research and development	16,094
Operating expenses	(38,166)	(9,198)
Other income (loss)
Foreign exchange	(12)	(3)
Amortization of deferred loan costs	(94)
Interest - net	(26)	75
Other loss (income)	(132)	72
Net loss for the year	(38,298)	(9,126)
Computation of basic loss per share
Net loss for the year	(38,298)	(9,126)
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance	(3,181)
Series A Preferred cash dividend	(8)	(8)
Series B Preferred stock dividend	(17)	(9)
Net loss for the year attributable to common stockholders	$ (41,504)	$ (9,143)
Basic and fully diluted loss per share	$ (1.60)	$ (0.87)
Basic and fully diluted weighted average number of shares	25,886,000	10,444,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive income	Preferred stock	Accumulated deficit
Beginning Balance at Jun. 30, 2019	$ 1,968	$ 4	$ 57,543	$ 21	$ 4,978	$ (60,578)
Beginning Balance, shares at Jun. 30, 2019		3,839,000
Issuance of shares and warrants - net of issue costs	6,583	$ 5	6,578
Issuance of shares and warrants - net of issue costs, shares		4,895,000
Exercise of pre-funded warrants for cash	26	$ 2	24
Exercise of pre-funded warrants for cash, shares		2,655,000
Exercise of warrants for cash	25		25
Exercise of warrants for cash, shares		25,000
Conversion of Series B preferred stock to common stock			174		(174)
Conversion of Series B preferred stock to common stock, shares		6,000
Shares issued for services	13		13
Shares issued for services, shares		23,000
Warrants issued for services	287		287
Stock option expense	495		495
Series A preferred cash dividend	(8)					(8)
Series B preferred stock dividend			9			(9)
Series B preferred stock dividend, shares		15,000
Loss for the year	(9,126)					(9,126)
Ending Balance at Jun. 30, 2020	263	$ 11	65,148	21	4,804	(69,721)
Ending Balance, shares at Jun. 30, 2020		11,458,000
Adgero merger (note 3)	16,725	$ 12	16,713
Adgero merger, shares		12,011,000
Issuance of Series C Preferred stock	25,028				25,028
Series C placement agent warrants			3,287		(3,287)
Series C Preferred stock share issuance costs	(3,455)				(3,455)
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance			3,181			(3,181)
Exercise of warrants for cash	4,404	$ 4	4,400
Exercise of warrants for cash, shares		4,677,000
Conversion of Series B preferred stock to common stock			4,525		(4,525)
Conversion of Series B preferred stock to common stock, shares		162,000
Conversion of Series C Preferred stock to common stock	3,713	$ 5	3,708		(3,713)
Conversion of Series C preferred stock to common stock, shares		4,251,000
Series C Agent Warrants exercised			(79)		79
Shares issued for services	0
Shares issued for services, shares		0
Warrants issued for services	569		569
Stock options exercised	77	$ 1	76
Stock options exercised, Shares		170,000
Stock option expense	5,276		5,276
Series A preferred cash dividend	(8)					(8)
Series B preferred stock dividend			17			(17)
Series B preferred stock dividend, shares		11,000
Loss for the year	(38,298)					(38,298)
Ending Balance at Jun. 30, 2021	$ 10,581	$ 33	$ 106,821	$ 21	$ 14,931	$ (111,225)
Ending Balance, shares at Jun. 30, 2021		32,740,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Loss for the year	$ (38,298)	$ (9,126)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of intangible assets	2	10
Depreciation of property and equipment	30
Impairment of in-process research and development	16,094
Change in fair value of milestone liability	(6)
Interest expense	30
Amortization of deferred loan costs	94
Shares issued for services		13
Warrants issued for services	569	193
Stock option expense	5,276	495
Changes in operating assets and liabilities
Prepaid expenses, deposits and other	(381)	(59)
Clinical trial deposits	(2,100)
Accounts payable and accrued liabilities	(67)	207
Related party payables	(103)	339
Net cash used in operating activities	(18,860)	(7,928)
Cash flows from investing activities
Cash acquired on merger with Adgero	969
Purchase of equipment	(8)
Proceeds on sale of equipment	3
Net cash provided by investing activities	964
Cash flows from financing activities
Net proceeds from the issuance of shares and warrants	21,598	6,583
Warrants exercised for cash	4,404	51
Stock options exercised for cash	77
Proceeds from loan	500
Repayment of loan	(500)
Interest paid	(30)
Deferred financing costs		(25)
Series A preferred cash dividend	(8)	(8)
Net cash provided by financing activities	26,041	6,601
Increase (decrease) in cash and cash equivalents	8,145	(1,327)
Cash and cash equivalents – beginning of year	2,392	3,719
Cash and cash equivalents – end of year	$ 10,537	$ 2,392

Nature of operations, corporate

Nature of operations, corporate history, and going concern and management plans	12 Months Ended
	Jun. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of operations, corporate history, and going concern and management plans	1 Nature of operations, corporate history, and going concern and management plans Nature of operations Kintara Therapeutics, Inc. (the “Company”) is a clinical stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage, Phase 3-ready therapeutics - VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates. Corporate history The Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”). On August 19, 2020, the Company completed its merger with Adgero Biopharmaceuticals Holdings, Inc. (“Adgero”) (note 3). In conjunction with the Adgero merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero, a Delaware corporation, which are clinical stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Adgero merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. (“Adgero Inc.”), formerly a wholly-owned subsidiary of Adgero. References to the Company refer to the Company and its wholly-owned subsidiaries. Going concern and management plans These consolidated financial statements have been prepared on a going concern basis which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business. For the year ended June 30, 2021, the Company reported a loss of $38,298 and a negative cash flow from operations of $18,860. The Company had an accumulated deficit of $111,225 and had cash and cash equivalents of $10,537 as of June 30, 2021. The Company is in the clinical stage and has not generated any revenues to-date. The Company does not have the prospect of achieving revenues until such time that its product candidates are commercialized, or partnered, which may not ever occur. Despite the receipt of approximately $13.6 million in net proceeds from a registered direct financing subsequent to June 30, 2021, in the near future, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within one year from the date of filing of these consolidated financial statements. Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. However, the coronavirus (“COVID-19”) pandemic has created significant economic uncertainty and volatility in the credit and capital markets. Management plans to secure the necessary financing through the issue of new equity and/or the entering into strategic partnership arrangements but the The Company may not be able to raise sufficient additional capital and may tailor its drug candidates development programs based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful. These financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Significant accounting policies	2 Significant accounting policies Basis of presentation The consolidated financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The principal accounting policies applied in the preparation of these consolidated financial statements are set out below and have been consistently applied to all years presented. Certain prior period balances have been reclassified to conform with the current year’s presentation. Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Inc., Del Mar BC, Callco, and Exchangeco as of, and for the years ended June 30, 2021 and 2020. All intercompany balances and transactions have been eliminated in consolidation. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the fair value of the milestone payment liability, the valuation of equity instruments issued for services, clinical trial accruals, deferred tax valuation allowance and assessment of going concern. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements. Cash and cash equivalents Cash and cash equivalents consist of cash and highly liquid investments with original maturities from the purchase date of three months or less that can be readily convertible into known amounts of cash. Cash and cash equivalents are held at recognized Canadian and United States financial institutions. Interest earned is recognized in the consolidated statement of operations. Foreign currency translation The functional currency of the Company at June 30, 2021 is the United States dollar. Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign-currency denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange losses or gains in the consolidated statement of operations. Non-monetary assets and liabilities are translated at historical exchange rates. Expenses are translated at average exchange rates during the period. Exchange gains and losses are included in consolidated statement of operations for the period. Acquired in-process research and development expense The Company acquired in-process research and development assets in connection with its Merger with Adgero. As the acquired in-process research and development assets were deemed to have no current or alternative future use, an expense of $16,094 was recognized in the consolidated statements of operations for the year ended June 30, 2021. Property and equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over its estimated useful life of three years. Depreciation expense is recognized from the date the equipment is put into use. Income taxes The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. To the extent that deferred tax assets cannot be recognized under the preceding criteria, the Company establishes valuation allowances, as necessary, to reduce deferred tax assets to the amounts expected to be realized. As of June 30, 2021, and 2020, all deferred tax assets were fully offset by a valuation allowance. The realization of deferred tax assets is dependent upon future federal, state and foreign taxable income. The Company’s judgments regarding deferred tax assets may change due to future market conditions, as the Company expands into international jurisdictions, due to changes in U.S. or international tax laws and other factors. These changes, if any, may require material adjustments to the Company’s deferred tax assets, resulting in a reduction in net income or an increase in net loss in the period in which such determinations are made. The Company recognizes the impact of uncertain tax positions based upon a two-step process. To the extent that a tax position does not meet a more-likely-than-not level of certainty, no impact is recognized in the consolidated financial statements. If a tax position meets the more-likely-than-not level of certainty, it is recognized in the consolidated financial statements at the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company’s policy is to analyze the Company’s tax positions taken with respect to all applicable income tax issues for all open tax years in each respective jurisdiction. Interest and penalties with respect to uncertain tax positions would be included in income tax expense. As of June 30, 2021, the Company concluded that there were no uncertain tax provisions required to be recognized in its consolidated financial statements. The Company does not record U.S. income taxes on the undistributed earnings of its foreign subsidiaries based upon the Company’s intention to permanently reinvest undistributed earnings to ensure sufficient working capital and further expansion of existing operations outside the United States. As June 30, 2021, the Company’s foreign subsidiaries operated at a cumulative deficit for U.S. earnings and profit purposes. In the event the Company is required to repatriate funds from outside of the United States, such repatriation would be subject to local laws, customs, and tax consequences. Determination of the amount of unrecognized deferred tax liability related to these earnings is not practicable. Financial instruments The Company has financial instruments that are measured at fair value. To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows: • Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and • Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. As of June 30, 2021, the Company’s milestone payment liability was measured using level 3 inputs (note 3). The Company’s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, and related party payables. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments. Intangible assets Website development costs Website development costs are stated at cost less accumulated amortization. The Company capitalizes website development costs associated with graphics design and development of the website application and infrastructure. Costs related to planning, content input, and website operations are expensed as incurred. The Company amortizes website development costs on a straight-line basis over three years. Patents Expenditures associated with the filing, or maintenance of patents, licensing or technology agreements are expensed as incurred. Costs previously recognized as an expense are not recognized as an asset in subsequent periods. Once the Company has achieved regulatory approval patent costs will be deferred and amortized over the remaining life of the related patent. Accruals for research and development expenses and clinical trials As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants, and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects of the expenses. The Company determines accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the years ended June 30, 2021 and 2020, there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials. Warrants and shares issued for services The Company has issued equity instruments for services provided by employees and non-employees. The equity instruments are valued at the fair value of the instrument issued. Stock options The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement of operations over the service period based on a measurement of fair value for each stock-based award. Prior to our adoption of ASU 2018-07, Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting For the years ended June 30, 2021 and 2020, the determination of grant-date fair value for stock option awards was estimated using the Black-Scholes model, which includes variables such as the expected volatility of our share price, the anticipated exercise behavior of its grantee, interest rates, and dividend yields. For years ended June 30, 2021 and 2020, the Company utilized the plain vanilla method to determine the expected life of stock options. These variables are projected based on our historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the years ended June 30, 2021 and 2020 diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, performance stock units, and convertible preferred shares is anti-dilutive. As of June 30, 2021, potential common shares of 6,974 (2020 – 10,309) related to outstanding common stock warrants, 2,100 (2020 – nil) related to outstanding Series C preferred stock warrants, 6,392 (2020 – 1,559) related to stock options, nil (2020 – 162) relating to outstanding Series B convertible preferred shares, and 17,295 (2020 – nil) relating to outstanding Series C convertible preferred shares were excluded from the calculation of net loss per common share. Segment information The Company identifies its operating segments based on business activities, management responsibility and geographical location. The Company operates within a single Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Not yet adopted Accounting Standards Update (“ASU”) 2020-06 — Debt - Debt with conversion and other options (subtopic 470-20) and derivatives and hedging – contracts in entity’s own equity (subtopic 815-40): accounting for convertible instruments and contracts in an entity’s own equity The amendments in this update are intended to simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. For public business entities that are not smaller reporting companies, the ASU’s amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. For all other entities, the effective date is for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The guidance may be early adopted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company has not yet evaluated the impact of adoption of this ASU on its consolidated financial statements and related disclosures. ASU 2020-10 — Codification Improvements The amendments in this update remove references to various FASB Concepts Statements, situates all disclosure guidance in the appropriate disclosure section of the Codification, and makes other improvements and technical corrections to the Codification. The amendments in Sections B and C of this amendment are effective for fiscal periods beginning after December 15, 2020, for public business entities. For all other entities, the amendments are effective for fiscal periods beginning after December 15, 2021, and interim periods within fiscal periods beginning after December 15, 2022. The Company has not yet evaluated the impact of adoption of this ASU on its consolidated financial statements and related disclosures. ASU 2021-04 — Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in this update are intended to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange and that are not within the scope of another FASB Accounting Standards Codification. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. The Company has not yet evaluated the impact of adoption of this ASU on its consolidated financial statements and related disclosures. During the year ended June 30, 2021, other than ASUs 2020-06, 2020-10, and 2021-04, there have been no new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s consolidated financial statements.

Merger

Merger	12 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
Merger	3 Merger On June 9, 2020, the Company, Adgero Acquisition Corp., a wholly-owned subsidiary of the Company (“Merger Sub”), and Adgero, entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) pursuant to which upon closing the Merger Sub will merge with and into Adgero, with Adgero surviving the merger and becoming a direct, wholly-owned subsidiary of the Company (the “Merger”). Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the “Effective Time”), (i) each outstanding share of Adgero common stock (the “Adgero Common Stock”) was converted into shares of Company common stock (the “Kintara Common Stock”) based on the exchange ratio, (ii) each outstanding warrant to purchase Adgero Common Stock was converted into a warrant exercisable for that number of shares of Kintara Common Stock equal to the product of (x) the aggregate number of shares of Adgero Common Stock for which such warrant was exercisable and (y) the Exchange Ratio (as defined in the Merger Agreement); and (iii) each outstanding Adgero stock option, whether vested or unvested, that had not been exercised was cancelled for no consideration. , the Merger The Exchange Ratio in the Merger Agreement was negotiated so that the existing stockholders of Adgero would own 49.5% of the total voting shares outstanding of the Company and the existing stockholders of the Company would own 50.5% of the total voting shares outstanding of the Company immediately after the merger (less the effect of the payment of cash in lieu of any fractional shares of Kintara Common Stock). The final Exchange Ratio determined immediately prior to the Effective Time to reflect the Company’s and Adgero’s capitalization as of immediately prior to such time was 1.574. Under the terms of the Merger Agreement, upon closing of the Merger, the Company issued 11,439 shares of Company common stock and 2,314 stock purchase warrants to the security holders of Adgero (“Adgero Warrants”). The Adgero Warrants are exercisable at $3.18 per share (note 8). The Adgero Warrants were valued using a Black-Scholes valuation with a weighted-average risk-free interest rate of 0.21%, a term of one year, a In connection with the Merger, the Company completed a private placement of Series C Convertible Preferred Stock in three separate closings (note 8). To determine the accounting for this transaction under ASU 2017-01, an assessment was made as to whether an integrated set of assets and activities should be accounted for as an acquisition of a business or an asset acquisition. The guidance requires an initial screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If that screen is met, the set is not a business. In connection with the Merger, substantially all of the fair value was concentrated in in-process research and development (“IPR&D”). As such, the Merger has been treated as an acquisition of Adgero assets and an assumption of Adgero liabilities. The Company incurred approximately $1,554 of legal, consulting and other professional fees related to the Merger, of which approximately $500 was incurred in the year ended June 30, 2021 (2020 - $1,054). The transaction costs applicable to the Merger have been classified as merger expenses in the consolidated statement of operations for the years ended June 30, 2021 and 2020. The following summarizes total consideration transferred to the Adgero stockholders under the Merger as well as the assets acquired and liabilities assumed under the Merger: $ (in thousands) Consideration: Common stock 15,328 Warrants 630 Success fee shares 766 16,724 Net assets acquired: Cash (969 ) Other current assets (11 ) Property and equipment (note 5) (175 ) Accounts payable and accrued liabilities 337 Milestone payment liability 188 In-process research and development 16,094 The fair value of the IPR&D assets has been expensed as a charge in the consolidated statements of operations for the year ended June 30, 2021 as there is no alternative use for these assets. Property and equipment includes office furniture that was subsequently sold and laboratory equipment that was put into use during the third quarter of the year ended June 30, 2021. The milestone payment liability relates to an asset purchase agreement with St. Cloud Investments, LLC (“St. Cloud”) that Adgero has regarding the acquisition of REM-001. The Agreement, as amended, is dated November 26, 2012 (the “St. Cloud Agreement”). Pursuant to the terms of the St. Cloud Agreement, the Company is obligated to make certain payments under the agreement. The future contingent amounts payable under that agreement are as follows: • Upon the earlier of (i) a subsequent equity financing to take place after the Company conducts a Phase 2B clinical study in which fifty patients complete the study and their clinical data can be evaluated or (ii) the commencement of a clinical study intended to be used as a definitive study for market approval in any country, the Company is obligated to pay an aggregate amount of $300 in cash or an equivalent amount of common stock, with $240 to St. Cloud and $60 to an employee of the Company; and • Upon receipt of regulatory approval of REM-001 Therapy, the Company is obligated to pay an aggregate amount of $700 in cash or an equivalent amount of common stock, with $560 to St. Cloud and $140 to an employee of the Company. With respect to the $300 and $700 potential milestone payments referenced above (each a “Milestone Payment”), if either such Milestone Payment becomes payable, and in the event the Company elects to pay either such Milestone Payment in shares of its common stock, the value of the common stock will equal the average of the closing price per share of the Company’s common stock over the twenty (20) trading days following the first public announcement of the applicable event described above. The milestone payment liability has been estimated using a scenario-based method (or “SBM”). An SBM is an income-based approach under which possible outcomes are identified, the contingent consideration payoff of each outcome is probability weighted, and then a suitable discount $ (in thousands) Balance – June 30, 2020 — Addition 188 Change in fair value estimate (6 ) Balance – June 30, 2021 182

Clinical Trial Deposit

Clinical Trial Deposit	12 Months Ended
	Jun. 30, 2021
Other Liabilities [Abstract]
Clinical Trial Deposit	4 Clinical trial deposit The Company has entered into an agreement with a contract research organization (“CRO”) for the management of the Company’s registration study for glioblastoma multiforme. Under the agreement, the Company will supply the drug for the study and the CRO will manage all operational aspects of the study including site activation and patient enrollment. The Company is required to make certain payments under the agreement related to patient enrollment milestones. For the year ended June 30, 2021, the Company has recognized $5,430 (2020 – nil) of expenses for this study. As part of study startup, the Company made an initial deposit payment of $2,600 to the CRO in relation to the commencement of the recruitment of patients. Of the $2,600 total, $500 was expensed during the year ended June 30, 2021 (2020 – nil). It is anticipated that the remainder of the deposit of $2,100 will be applied to future invoices, or refunded to the Company, of which $500 is anticipated to be applied in the near term and $1,600 beyond twelve months from June 30, 2021. The Company can terminate the study at any time. Upon termination, the Company will be liable for any payments due to the effective date of the termination as well as any non-refundable or non-cancellable costs incurred by the CRO prior to the date of termination.

Property Equipment and Intangib

Property Equipment and Intangibles	12 Months Ended
	Jun. 30, 2021
Property Plant And Equipment [Abstract]
Property Equipment and Intangibles	5 Property, equipment and intangibles Property, equipment and intangibles $ (thousands) Balance, June 30, 2019 12 Less amortization (10 ) Balance, June 30, 2020 2 Acquired in Adgero merger (note 3) 175 Laboratory equipment purchased 8 Disposal of furniture (3 ) Property and equipment 182 Less depreciation and amortization (32 ) Balance, June 30, 2021 150 At June 30, 2021, the total capitalized cost of intangibles was $80 (2020 - $80) and the Company has recognized $2 and $10, respectively, in amortization expense during the years ended June 30, 2021 and 2020.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related party transactions	6 Related party transactions Valent Technologies, LLC Agreements One of the Company’s officers is a principal of Valent Technologies, LLC (“Valent”) and as result Valent is a related party to the Company. On September 12, 2010, the Company entered into a Patent Assignment Agreement (the “Valent Assignment Agreement”) with Valent pursuant to which Valent transferred to the Company all its right, title and interest in and to the patents for VAL-083 owned by Valent. The Company now owns all rights and title to VAL-083 and is responsible for the drug’s further development and commercialization. In accordance with the terms of the Valent Assignment Agreement, Valent is entitled to receive a future royalty on all revenues derived from the development and commercialization of VAL-083. In the event that the Company terminates the agreement, the Company may be entitled to receive royalties from Valent’s subsequent development of VAL-083 depending on the development milestones the Company has achieved prior to the termination of the Valent Assignment Agreement. On September 30, 2014, the Company entered into an exchange agreement (the “Valent Exchange Agreement”) with Valent and Del Mar (BC). Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of $279 (including aggregate accrued interest to September 30, 2014 of $29), issued to Valent by Del Mar (BC), for 279 shares of the Company’s Series A Preferred Stock. The Series A Preferred Stock has a stated value of $1.00 per share (the “Series A Stated Value”) and is not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Series A Stated Value per year, payable quarterly in arrears. For the years ended June 30, 2021 and 2020 respectively, the Company recorded $8 Related party payables At June 30, 2021 there is an aggregate amount of $561 (2020 - $664) payable to the Company’s officers and directors for fees, expenses, and accrued bonuses and other liabilities.

Loan from National Brain Tumor

Loan from National Brain Tumor Society and National Foundation for Cancer Research	12 Months Ended
	Jun. 30, 2021
Loans Payable [Abstract]
Loan from National Brain Tumor Society and National Foundation for Cancer Research	7 Loan from National Brain Tumor Society and National Foundation for Cancer Research $ (in thousands) Balance – June 30, 2020 — Funding 500 Financing costs (94 ) Interest expense 30 Amortization of deferred financing costs 94 Payment of principal and interest (530 ) Balance – June 30, 2021 — During the year ended June 30, 2021, the Company received a loan of $500 from National Brain Tumor Society (“NBTS”) and the National Foundation for Cancer Research (the “NBTS Loan”) to support VAL-083's preparation for participation in the Global Coalition for Adaptive Research's sponsored trial, Adaptive Global Innovative Learning Environment study. In relation to the NBTS Loan, the Company issued 125 share purchase warrants which are exercisable at a price of $1.09 per common share until June 19, 2025 and were included in deferred financing costs as of June 30, 2020 (“NBTS Warrants”). The NBTS Loan is secured by a promissory note, accrues interest at a rate of 6% per annum and matures on June 19, 2021. On June 19, 2021, the Company repaid the NBTS Loan principal of $500 and loan interest of $30. The NBTS Warrants were valued at $94 using a Black-Scholes valuation with a risk-free interest rate of 0.37%, a term of 5 years, a volatility of 89.82%, and a dividend rate of 0%. The estimated volatility of the Company’s common stock at the date of measurement is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the instrument at the valuation date. The expected term has been estimated using the remaining life of the NBTS Warrants.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Stockholders' Equity	8 Stockholders’ equity Preferred stock Series C Preferred stock Series C Preferred Stock Number of shares $ (in thousands) Balance – June 30, 2019 and 2020 — — Issuance 25,028 18,286 Issued on exercise of Series C Agent Warrants 33 79 Conversion of Series C Preferred stock to common stock (4,969 ) (3,713 ) Balance – June 30, 2021 20,092 14,652 In connection with the Merger (note 3), the Company issued 25,028 shares of Series C Convertible Preferred Stock (the “Series C Preferred Stock”) in three separate closings of a private placement (Series C-1, C-2, and C-3) in August, 2020. Each share of Series C Preferred Stock was issued at a purchase price of $1,000 per share and is convertible into shares of common stock based on the respective conversion prices which were determined at the closing of each round of the private placement. Subject to ownership limitations, the owners of the Series C Preferred Stock are entitled to receive dividends, payable in shares of common stock at a rate of 10%, 15%, 20% and 25% of the number of shares of common stock issuable upon conversion of the Series C Preferred Stock, on the 12 th th th th Total gross proceeds from the private placement were $25,028, or approximately $21,573 in net proceeds after deducting financing costs of $3,455 with respect to agent commissions and expenses, as well as legal and accounting fees. Of the total financing costs, $ 85 was deferred as of June 30, 2020. In addition, the Company issued 2,504 Series C Preferred Stock purchase warrants with a fair value of $ 3,287 to the placement agent (“Series C Agent Warrants”) . The conversion prices for the Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series C-3 Preferred Stock are $1.16, $1.214 and $1.15, respectively. Based on the conversion prices of the three respective classes of the Series C Preferred Stock, the originally issued 25,028 shares of Series C Preferred Stock were convertible into an aggregate of 21,516 shares of common stock. The cumulative dividends to be issued on the 12 th th th th The Company’s Series C Preferred Stock outstanding, conversion shares, and future dividends as of June 30, 2021 are as follows: Series Number Conversion Price $ Number of conversion shares (in thousands) Dividend Shares (in thousands) Series 1 16,564 1.16 14,279 9,995 Series 2 1,148 1.21 946 662 Series 3 2,380 1.15 2,070 1,449 20,092 17,295 12,106 Series C Dividends Dividend Shares (in thousands) 10% - August 19, 2021 1,729 15% - August 19, 2022 2,594 20% - August 19, 2023 3,459 25% - August 19, 2024 4,324 12,106 The conversion feature of the Series C Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series C Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $3,181 related to the beneficial conversion feature arising from the issuance of Series C Convertible Preferred Stock. This non-cash deemed dividend increased the Company’s net loss attributable to common stockholders and net loss per share. The Series C Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company’s common stock and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series C Preferred Stock. The Series C Preferred Stock shall be pari passu in liquidation to the Company’s Series A and Series B Preferred Stock. The liquidation value of the Series C Preferred Stock at June 30, 2021 is the stated value of $20,092. Series B Preferred stock Series B Preferred Stock (in thousands) Number of shares $ Balance – June 30, 2019 674 4,699 Conversion of Series B Preferred stock to common stock (25 ) (174 ) Balance – June 30, 2020 649 4,525 Conversion of Series B Preferred stock to common stock (649 ) (4,525 ) Balance – June 30, 2021 — — During the year ended June 30, 2016, the Company issued an aggregate of 902 shares of Series B Preferred Stock at a purchase price of $8.00 per share. Each share of Series B Preferred Stock was convertible into 0.25 shares of common stock equating to a conversion price of $32.00 (the “Conversion Price”) and automatically converted to common stock on April 29, 2021. T The liquidation value of the Series B Preferred Stock at June 30, 2021 was the stated value of $nil (2020 - $5,189). In addition, in relation to the VAL-083 compound, the Company and the former holders of the Series B Preferred Stock entered into a royalty agreement pursuant to which the Company will pay the former holders of the Series B Preferred Stock, in aggregate, a single-digit royalty based on their pro rata ownership of the former Series B Preferred Stock on products sold directly by the Company or sold pursuant to a licensing or partnering arrangement (the “Royalty Agreement”). Rights to the royalties vested during the first three years following the applicable original closing dates in equal thirds to the former holders of the Series B Preferred Stock on each of the three vesting dates. Upon such vesting dates, the royalty amounts became vested royalties. If the holder converted their Series B Preferred Stock to common stock prior to a respective vesting date, such holder forfeited any royalty rights that had not vested prior to such conversion date and shall no longer receive ongoing future royalty payments under the Royalty Agreement but will be entitled to receive any residual royalty payments that have vested. Pursuant to the Series B Preferred Stock dividend, during the year ended June 30, 2021, the Company issued 11 (2020 – 15) shares of common stock and recognized $17 (2020 – $9) as a direct increase in accumulated deficit. Prior to mandatory conversion to common stock on April 29, 2021, during the year ended June 30, 2021, a total of 48 (2020 – 25) shares of Series B Preferred Stock were converted for an aggregate 12 On April 29, 2021, the remaining 601 shares of Series B Preferred Stock were converted into 150 shares of common stock pursuant to the five-year Series A Preferred Stock Effective September 30, 2014, the Company filed a Certificate of Designation of Series A Preferred Stock (the “Series A Certificate of Designation”) with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated 279 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of $1.00 per share (the “Series A Stated Value”) and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Series A Stated Value per year, payable quarterly in arrears. Upon any liquidation of the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available for distribution to stockholders, the Series A Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued but unpaid dividends thereon, prior to any payments being made with respect to the common stock. The Series A Preferred Stock is held by Valent (note 6). The Series A Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company’s common stock, and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series A Preferred Stock. The Series A Preferred Stock shall be pari passu in liquidation to the Company’s Series B and Series C Preferred Stock. The liquidation value of the Series A Preferred stock at June 30, 2021 of $279. There was no change to the Series A Preferred stock for the years ended June 30, 2021 or 2020. Common stock Amended articles of incorporation On June 25, 2021, the Company amended its articles of incorporation to increase the number of authorized shares of common stock from 95,000 to 175,000 shares. Stock Issuances Year ended June 30, 2020 Underwritten public offering On August 16, 2019, the Company closed on the sale of (i) 4,895 shares of its common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 2,655 shares of Common Stock and (iii) common warrants to purchase an aggregate of 7,763 shares of Common Stock (“2020 Investor Warrants”), including 800 shares of Common Stock and 2020 Investor Warrants to purchase an aggregate of 1,013 shares of Common Stock sold pursuant to a partial exercise by the underwriters of the underwriters’ option to purchase additional securities, in the Company’s underwritten public offering (the “Offering”). Each share of Common Stock or PFW, as applicable, was sold together with a 2020 Investor Warrant to purchase one share of Common Stock at a combined effective price to the public of $1.00 per share of Common Stock and accompanying 2020 Investor Warrant. The net proceeds from the Offering, including from the partial exercise of the underwriters’ option to purchase additional securities, were $6,583 after deducting underwriting discounts and commissions, and other offering expenses. The 2020 Investor Warrants are exercisable at $1.00 per share until their expiry on August 16, 2024 and the PFW are exercisable at $0.01 per share at any time after August 16, 2019. The Company also issued 377 warrants to the underwriters of the Offering. The underwriter warrants are exercisable at $1.15 per share commencing February 10, 2020 until their expiry on August 14, 2022. During the year ended June 30, 2020, all of the 2,655 PFW were exercised at $0.01 per PFW for proceeds of $27. Shares issued for services During the year ended June 30, 2021, the Company issued nil 2017 Omnibus Incentive Plan As subsequently approved by the Company’s stockholders at an annual meeting of stockholders on April 11, 2018, the Company’s board of directors approved adoption of the Company’s 2017 Omnibus Equity Incentive Plan (the “2017 Plan”). The board of directors also approved a form of Performance Stock Unit Award Agreement to be used in connection with grants of performance stock units (“PSUs”) under the 2017 Plan. As approved by the Company’s stockholders on June 25, 2021, the number of common shares available under the 2017 Plan was increased to 13,000 shares. Under the 2017 Plan 13,000 shares of Company common stock are currently reserved for issuance, less the number of shares of common stock issued under the Del Mar (BC) 2013 Amended and Restated Stock Option Plan (the “Legacy Plan”), or that are subject to grants of stock options made, or that may be made, under the Legacy Plan, or that have been previously exercised. A total of 136 shares of common stock have been issued under the Legacy Plan and/or are subject to outstanding stock options granted under the Legacy Plan, and a total of 6,256 shares of common stock have been issued under the 2017 Plan and/or are subject to outstanding stock options granted under the 2017 Plan leaving 6,414 shares of common stock available at June 30, 2021 for issuance under the 2017 Plan if all such options under the Legacy Plan were exercised, net of stock options previously exercised. The maximum number of shares of Company common stock with respect to which any one participant may be granted awards during any calendar year is 8% of the Company’s fully diluted shares of common stock on the date of grant (excluding the number of shares of common stock issued under the 2017 Plan and/or the Legacy Plan or subject to outstanding awards granted under the 2017 Plan and/or the Legacy Plan). No award will be granted under the 2017 Plan on or after July 7, 2027, but awards granted prior to that date may extend beyond that date. During the year ended June 30, 2021, a total of 223 options to purchase shares of common stock issued to directors of the Company were amended such that the period to exercise vested options to purchase shares of common stock from the date of termination of continuous service with the Company was extended from 90 days to one year. Of the total, th During the year ended June 30, 2021, a total of 4,834 options to purchase shares of common stock were granted to executive officers and directors of the Company. Of these, 4,699 have an exercise price of $1.70 per share, 60 have an exercise price of $1.355 per share, and 75 have an exercise price of $1.37. Of the total granted, 4,279 options to purchase shares of common stock vest as to 1/6 on the six-month anniversary of the grant date with the remaining portion vesting in equal monthly installments over a period of 30 months commencing on the seven-month anniversary of the grant date, 480 vest in 12 equal monthly installments beginning on October 15, 2020, and 75 vest as to 1/6 on the twelve-month anniversary of the grant date with the remaining portion vesting in equal quarterly installments over a period of eight quarters commencing on the fifteen-month anniversary of the grant date. All of the options to purchase shares of common stock granted have a 10-year term and are subject to cancellation upon the grantees’ termination of service for the Company, with certain exceptions. Stock Options The following table sets forth changes in stock options outstanding under all plans: Number of stock options outstanding (in thousands) Weighted average exercise price Balance – June 30, 2019 288 22.31 Granted 1,291 0.63 Forfeited (19 ) 0.61 Expired (1 ) 40.00 Balance – June 30, 2020 1,559 4.61 Granted 5,074 1.67 Exercised (195 ) 0.61 Expired (32 ) 34.88 Forfeited (14 ) 1.42 Balance – June 30, 2021 6,392 2.26 The following table summarizes stock options outstanding and exercisable under all plans at June 30, 2021: Exercise price $ Number Outstanding at June 30, 2021 (in thousands) Weighted average remaining contractual life (years) Number exercisable at June 30, 2021 (in thousands) 0.61 816 8.18 729 0.74 250 8.37 62 1.36 300 9.23 75 1.37 75 9.83 — 1.70 4,699 9.21 1,415 6.10 25 7.36 24 7.00 3 6.98 3 8.70 12 6.34 12 9.83 83 6.89 83 10.60 4 6.79 4 11.70 30 1.66 30 16.14 3 0.92 3 20.00 9 0.59 9 21.10 11 6.02 11 29.60 5 3.60 5 37.60 5 4.61 5 41.00 4 5.36 4 42.00 30 2.13 30 44.80 3 4.61 3 49.50 13 5.63 13 53.20 8 4.85 8 61.60 1 1.75 1 92.00 3 1.92 3 6,392 2,532 Included in the number of stock options outstanding are 2.5 stock options granted at an exercise price of CA$20.00. The exercise price of these options shown in the above table have been converted to US$16.14 using the period ending closing exchange rate. Stock options issued during the years ended June 30, 2021 and 2020 have been valued using a Black-Scholes pricing model with the following assumptions: June 30, 2021 June 30, 2020 Dividend rate — % — % Volatility 103% to 152% 89% to 102% Risk-free rate 0.19% to 1.28% 0.32% to 1.50% Term – years 0.4 to 5.9 4.7 to 5.7 The estimated volatility of the Company’s common stock at the date of issuance of the stock options is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the stock options at the valuation date. The expected life of the stock options has been estimated using the plain vanilla method. The Company has recognized the following amounts as stock option expense for the periods noted: Years ended June 30, 2021 $ 2020 $ Research and development 1,478 87 General and administrative 3,798 408 5,276 495 All of the stock option expense for the periods ended June 30, 2021 and 2020 has been recognized as additional paid in capital. The aggregate intrinsic value of stock options outstanding at June 30, 2021 was $4,759 (2020 - $80) and the aggregate intrinsic value of stock options exercisable at June 30, 2021 was $2,181 (2020 - $35). As of June 30, 2021, there was $3,014 in unrecognized compensation expense that will be recognized over the next 2.25 years. The following table sets forth changes in unvested stock options under all plans: Number of options (in thousands) Weighted average exercise price $ Unvested at June 30, 2019 85 11.35 Granted 1,291 0.63 Vested (500 ) 1.87 Forfeited (18 ) 0.61 Unvested at June 30, 2020 858 0.98 Granted 5,074 1.67 Vested (2,058 ) 1.52 Forfeited (14 ) 1.42 Unvested at June 30, 2021 3,860 1.60 The aggregate intrinsic value of unvested stock options at June 30, 2021 was $2,577 (2020 - $45). The unvested stock options have a remaining weighted average contractual term of 9.16 (2020 – 9.19) years. Common Stock Warrants The following table sets forth changes in outstanding warrants: Number of warrants (in thousands) Weighted average exercise price $ Balance – June 30, 2019 1,543 12.60 Underwritten public offering 10,418 0.75 Issuance of 2020 Underwriter Warrants 377 1.15 Exercise of PFW (2,655 ) 0.01 Exercise of 2020 Investor Warrants (25 ) 1.00 Warrants issued for services (i) 655 0.77 Expiry of warrants issued for services (i) (4 ) 59.30 Balance – June 30, 2020 10,309 2.71 Issuance of Adgero Warrants 2,314 3.18 Exercise of warrants (ii) (4,907 ) 1.00 Warrants issued for services (i) 600 1.74 Expiry of warrants (1,342 ) 6.00 Balance – June 30, 2021 6,974 3.34 i) Warrants issued for services are exercisable at various prices and expire at the various dates noted in the table below. ii) A total of 4,404 2020 Investor Warrants were exercised at $1.00 per share and 503 warrants issued as either agent warrants or issued for services were exercised on a cashless basis for which 273 common shares were issued. The following table summarizes the Company’s outstanding warrants as of June 30, 2021: Description of warrants Number (in thousands) Exercise price $ Expiry date 2020 Investor warrants 3,333 1.00 August 16, 2024 2019 Investor warrants 760 3.10 June 5, 2024 2018 Investor warrants 280 12.50 September 22, 2022 2017 Investor warrants 208 35.00 April 19, 2022 NBTS Warrants (i) 125 1.09 June 19, 2025 Warrants issued for services 6 17.80 January 25, 2023 Warrants issued for services 34 11.70 February 27, 2023 Warrants issued for services 12 9.00 September 15, 2023 Warrants issued for services 2 9.00 October 11, 2023 Warrants issued for services 280 0.75 November 18, 2023 Warrants issued for services 125 0.64 January 20, 2024 Warrants issued for services 330 1.49 September 22, 2023 Warrants issued for services 50 1.82 November 13, 2023 Warrants issued for services 100 1.47 January 7, 2024 Warrants issued for services 70 2.75 February 17, 2024 Warrants issued for services 50 2.38 February 25, 2024 2019 Agent warrants 47 3.88 June 3, 2024 2018 Agent warrants 40 12.50 September 20, 2022 2017 Agent warrants 14 40.60 April 12, 2022 Adgero Warrants (ii) 353 3.18 August 31, 2021 Adgero Warrants 755 3.18 January 17, 2022 6,974 (i) NBTS Warrants were issued with respect to loan proceeds received during the year ended June 30, 2021 (note 7). (i i ) Expired unexercised subsequent to June 30, 2021. Series C Preferred Stock Warrants In connection with the Series C Preferred Stock private placement, the Company initially issued 2,504 Series C Agent Warrants. The Series C Agent Warrants have an exercise price of $1,000 per share, provide for a cashless exercise feature, and are exercisable for a period of four years from August 19, 2020. The Series C Preferred Stock issuable upon exercise of the Series C Agent Warrants is convertible into shares of common stock in the same manner as each respective underlying series of outstanding Series C Preferred Stock and will be entitled to the same dividend rights as each respective series. The Series C Agent Warrants were valued at a total of $3,287 using a binomial pricing model with a risk-free interest rate of 0.27%, a term of 4.0 years, and a volatility of 95.2% to 95.8%. The estimated volatility of the Company’s common stock at the date of measurement is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining life of the instrument at the valuation date. The expected term has been estimated using the contractual term of the warrant. The following table sets forth changes in outstanding Series C Agent Warrants: Balance June 30, 2020 Number of Warrants Issued Number of Warrants Exercised Balance, June 30, 2021 Exercise price $ Issuance of Preferred Series C-1 Agent Warrants — 1,959 (30 ) 1,929 1.16 Issuance of Preferred Series C-2 Agent Warrants — 219 — 219 1.21 Issuance of Preferred Series C-3 Agent Warrants — 326 (30 ) 296 1.15 — 2,504 (60 ) 2,444 The following table summarizes the Company’s outstanding Series C Agent Warrants as of June 30, 2021: Series C Agent Warrants Number Conversion price $ Number of conversion shares (in thousands) Cumulative common stock dividends (in thousands) Series 1 1,929 1.16 1,663 1,164 Series 2 219 1.21 180 126 Series 3 296 1.15 257 180 2,444 2,100 1,470

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	9 Income taxes For the years ended June 30, 2021, and 2020, the Company did not record a provision for income taxes due to a full valuation allowance against the deferred tax assets. Significant components of the Company’s deferred tax assets and deferred tax liabilities are shown below: June 30, 2021 $ June 30, 2020 $ Deferred tax assets: Non-capital losses carried forward 20,148 11,871 Stock-based compensation 155 — Capital losses carried forward 18 18 Financing costs 326 221 Scientific research and development 761 604 Scientific research and development – Investment Tax Credits (“ITC”) 665 534 22,073 13,248 Deferred tax liabilities: Scientific research and development – ITC (110 ) (88 ) 21,963 13,160 Valuation allowance (21,963 ) (13,160 ) Net future tax assets — — The income tax benefit of these tax attributes has not been recorded in these consolidated financial statements because of the uncertainty of their recovery. The Company’s effective income tax rate differs from the statutory income tax rate of 21% (2020 – 21%). The differences arise from the following items: June 30, 2021 $ June 30, 2020 $ Tax recovery at statutory income tax rates (8,015 ) (1,916 ) Permanent differences 4,506 142 Effect of rate differentials between jurisdictions (551 ) (239 ) Effect of foreign exchange rates (954 ) 347 Non-capital losses acquired with Adgero (4,114 ) — Scientific research and development – ITC 97 (38 ) Adjustment to prior year's provision versus statutory tax returns 228 323 Change in valuation allowance 8,803 1,381 — — The Company has no current income tax expense for the year ended June 30, 2021, as there was a taxable loss for this period. The components of the Company’s loss before income taxes for the year ended June 30, 2021 were allocated as to $29.0 million in the U.S. and $9.2 million in Canada. As of June 30, 2021, the Company had combined U.S. and Canadian net operating loss (“NOL”) carry forwards of $77.7 million (2020 – $47.8 million). The U.S. federal NOL carryforwards consist of $15.8 million generated before July 1, 2018, which begin expiring in 2026, and $20.4 million that can be carried forward indefinitely, but are subject to the 80% taxable income limitation. The Canadian NOL carryforwards of $41.5 million begin expiring in 2030. In addition, the Company has non-refundable Canadian federal investment tax credits of $407 (2020 - $329) that expire between 2031 and 2040 and non-refundable British Columbia investment tax credits of $258 (2020 – $205) that expire between 2021 and 2030. The Company also has Canadian scientific research and development tax incentives of $2.8 million (2020 – $2.2 million) that do not expire. The Company files U.S. federal, U.S. state, and Canadian income tax returns with varying statues of limitations. The tax years from 2007 to 2021 remain open to examination due to the carryover of unused NOL carryforwards and tax credits. The Company currently is not under examination by any tax authority. Internal Revenue Code (“IRC”) Section 382 and 383 places a limitation on the amount of taxable income that can be offset by NOL and credit carryforwards after a change in control (generally greater than 50% change in ownership within a three-year The CARES Act, was enacted March 27, 2020. Among the business provision, the CARES Act provided for various payroll tax incentives, changes to net operating loss carryback and carryforward rules, business interest expense limitation increases, and bonus depreciation on qualified improvement property. Additionally, the Consolidated Appropriations Act of 2021 was signed on December 27, 2020 which provided additional COVID-19 relief provisions for businesses. The Company has evaluated the impact of both the Acts and has determined that any impact is not material to its financial statements.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and contingencies	10 Commitments and contingencies The Company has the following obligations over the next five fiscal years ending June 30, 2026: Clinical development The Company has entered into contracts for drug manufacturing, clinical study management and safety related to its clinical trials Office lease The Company currently rents its shared head office on a one-year

Supplementary Statement of Cash

Supplementary Statement of Cash Flows Information	12 Months Ended
	Jun. 30, 2021
Supplemental Cash Flow Elements [Abstract]
Supplementary statement of cash flows information	11 Supplementary statement of cash flows information Year ended June 30, 2021 Year ended June 30, 2020 Series B Preferred Stock common stock dividend (note 8) 17 9 Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance (note 8) 3,181 — Non-cash issue costs (note 8) 3,287 182 Deferred costs in accounts payable — 60 Warrants issued as deferred costs (note 7) — 94 Cashless exercise of Series C warrants (note 8) 79 — Conversion of Series B Preferred Stock to common stock (note 8) 4,525 174 Conversion of Series C Preferred Stock to common stock (note 8) 3,713 — Income taxes paid — — Interest paid — —

Financial Risk Management

Financial Risk Management	12 Months Ended
	Jun. 30, 2021
Risks And Uncertainties [Abstract]
Financial Risk Management	12 Financial risk management Market risk Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company’s income or valuation of its financial instruments. The Company is exposed to financial risk related to fluctuation of foreign exchange rates. Foreign currency risk is limited to the portion of the Company’s business transactions denominated in currencies other than the United Sates dollar, primarily general and administrative expenses incurred in Canadian dollars. The Company believes that the results of operations, financial position and cash flows would be affected by a sudden change in foreign exchange rates but would not impair or enhance its ability to pay its Canadian dollar accounts payable. The Company manages foreign exchange risk by converting its US$ to CA$ as needed. The Company maintains the majority of its cash in US$. As of June 30, 2021, Canadian dollar denominated accounts payable and accrued liabilities exposure in US$ totaled $59. a) Foreign exchange risk Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. If foreign exchange rates were to fluctuate within +/-10% of the closing rate at year-end, the maximum exposure is $10. Balances in foreign currencies at June 30, 2021 and 2020 were as follows: June 30, 2021 balances CA$ June 30, 2020 balances CA$ Trade payables 114 167 Cash 30 21 Interest, taxes, and other receivables 11 13 b) Interest rate risk The Company is subject to interest rate risk on its cash and cash equivalents and believes that the results of operations, financial position and cash flows would not be significantly affected by a sudden change in market interest rates relative to the investment interest rates due to the short-term nature of the investments. As of June 30, 2021, cash and cash equivalents held by the Company were $10,537. The Company’s cash balance currently earns interest at standard bank rates. If interest rates were to fluctuate within +/-10% of the closing rate at year end the impact of the Company’s interest-bearing accounts will be not be significant due to the current low market interest rates. The only financial instruments that expose the Company to interest rate risk are its cash and cash equivalents. Liquidity risk Liquidity risk is the risk that the Company will encounter difficulty in raising funds to meet cash flow requirements associated with financial instruments. The Company continues to manage its liquidity risk based on the outflows experienced for the period ended June 30, 2021 and is undertaking efforts to conserve cash resources wherever possible. The maximum exposure of the Company’s liquidity risk is $2,962 as of June 30, 2021. Credit risk Credit risk arises from cash and cash equivalents, deposits with banks, financial institutions, and contractors as well as outstanding receivables. The Company limits its exposure to credit risk, with respect to cash and cash equivalents, by placing them with high quality credit financial institutions. The Company’s cash equivalents consist primarily of operating funds with commercial banks. Of the amounts with financial institutions on deposit, the following table summarizes the amounts at risk should the financial institutions with which the deposits are held cease trading: The maximum exposure of the Company’s credit risk is $8 at June 30, 2021 relating to interest, taxes, and other receivables. The credit risk related to uninsured cash and cash equivalents balances is $9,909 at June 30, 2021. Cash and cash equivalents $ Insured amount $ Non- insured amount $ 10,537 628 9,909 Concentration of credit risk Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents. The Company places its cash and cash equivalents in accredited financial institutions and therefore the Company’s management believes these funds are subject to minimal credit risk. The Company has no significant off-balance sheet concentrations of credit risk such as foreign currency exchange contracts, option contracts or other hedging arrangements.

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent events	13 Subsequent events The Company has evaluated its subsequent events from June 30, 2021 through the date these consolidated financial statements were issued and has determined that there are no subsequent events requiring disclosure in these consolidated financial statements other than the items noted below. Registered direct financing On September 24, 2021, the Company announced it had entered into securities purchase agreements with certain investors to raise approximately $15 million in gross proceeds, before placement agent fees and other offering expenses payable by the Company, through the issuance of 7,200,000 shares of its common stock, 4,800,000 pre-funded warrants, and investor warrants to purchase up to an aggregate of 12,000,000 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock, or pre-funded warrant, was together with one investor warrant to purchase one share of common stock offered at a combined price of $1.25. The pre-funded warrants are exercisable at $0.001 per share until they are exercised in full. The investor warrants have an exercise price of $1.25 per share and are exercisable for three and one half years from the date of issuance. In addition, the Company will issue 600,000 agent warrants exercisable at $ 1.5625 per share. The closing of the offering occu r r ed on September 28, 2021. Series C Preferred Stock On August 19, 2021, the Company paid the common stock dividend on its Series C Preferred Stock as well as the Series C Agent Warrants. The common stock dividend corresponds to the 10% dividend payable on the first anniversary of the initial closing of the Series C Preferred Stock which occurred on August 19, 2020. The 10% stock dividend is payable on August 19, 2021 to the holders of the Series C Preferred Stock and the Series C Agent Warrants on that date. No dividends are payable on Series C Preferred Stock or Series C Agent Warrants that were converted, or exercised, prior to August 19, 2021. The dividend resulted in 1,698 shares of common stock being issued to the Series C Preferred Stock holders and 210 shares of common stock being accrued to the Series C Agent Warrants holders. The common stock accrued to the Series C Agent Warrants holders will be released to the Series C Agent Warrant holders upon the exercise of the respective Series C Agent Warrant. Subsequent to June 30, 2021, 1,125 shares of Series C-1 Preferred Stock were converted into 970 shares of common stock, 250 shares of Series C-2 Preferred Stock were converted into 206 shares of common stock, and 335 shares of Series C-3 Preferred Stock were converted into 291 shares of common stock. Warrants Subsequent to June 30, 2021, 69 warrants were exercised at $1.00 per share and 353 warrants exercisable at $3.18 per share expired. Stock Options Subsequent to June 30, 2021, 435 stock options were issued to directors of the Company. The stock options are exercisable at $1.24 per share until September 22, 2031. The options vest in 12 equal monthly installments commencing October 22, 2021.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation The consolidated financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar. The principal accounting policies applied in the preparation of these consolidated financial statements are set out below and have been consistently applied to all years presented. Certain prior period balances have been reclassified to conform with the current year’s presentation.
Consolidation	Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Inc., Del Mar BC, Callco, and Exchangeco as of, and for the years ended June 30, 2021 and 2020. All intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the fair value of the milestone payment liability, the valuation of equity instruments issued for services, clinical trial accruals, deferred tax valuation allowance and assessment of going concern. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these consolidated financial statements.
Cash and Cash Equivalents	Cash and cash equivalents Cash and cash equivalents consist of cash and highly liquid investments with original maturities from the purchase date of three months or less that can be readily convertible into known amounts of cash. Cash and cash equivalents are held at recognized Canadian and United States financial institutions. Interest earned is recognized in the consolidated statement of operations.
Foreign Currency Translation	Foreign currency translation The functional currency of the Company at June 30, 2021 is the United States dollar. Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign-currency denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange losses or gains in the consolidated statement of operations. Non-monetary assets and liabilities are translated at historical exchange rates. Expenses are translated at average exchange rates during the period. Exchange gains and losses are included in consolidated statement of operations for the period.
Acquired In-process Research And Development Expense	Acquired in-process research and development expense The Company acquired in-process research and development assets in connection with its Merger with Adgero. As the acquired in-process research and development assets were deemed to have no current or alternative future use, an expense of $16,094 was recognized in the consolidated statements of operations for the year ended June 30, 2021.
Property, Plant and Equipment, Policy	Property and equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over its estimated useful life of three years. Depreciation expense is recognized from the date the equipment is put into use.
Income Taxes	Income taxes The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to the differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. To the extent that deferred tax assets cannot be recognized under the preceding criteria, the Company establishes valuation allowances, as necessary, to reduce deferred tax assets to the amounts expected to be realized. As of June 30, 2021, and 2020, all deferred tax assets were fully offset by a valuation allowance. The realization of deferred tax assets is dependent upon future federal, state and foreign taxable income. The Company’s judgments regarding deferred tax assets may change due to future market conditions, as the Company expands into international jurisdictions, due to changes in U.S. or international tax laws and other factors. These changes, if any, may require material adjustments to the Company’s deferred tax assets, resulting in a reduction in net income or an increase in net loss in the period in which such determinations are made. The Company recognizes the impact of uncertain tax positions based upon a two-step process. To the extent that a tax position does not meet a more-likely-than-not level of certainty, no impact is recognized in the consolidated financial statements. If a tax position meets the more-likely-than-not level of certainty, it is recognized in the consolidated financial statements at the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company’s policy is to analyze the Company’s tax positions taken with respect to all applicable income tax issues for all open tax years in each respective jurisdiction. Interest and penalties with respect to uncertain tax positions would be included in income tax expense. As of June 30, 2021, the Company concluded that there were no uncertain tax provisions required to be recognized in its consolidated financial statements. The Company does not record U.S. income taxes on the undistributed earnings of its foreign subsidiaries based upon the Company’s intention to permanently reinvest undistributed earnings to ensure sufficient working capital and further expansion of existing operations outside the United States. As June 30, 2021, the Company’s foreign subsidiaries operated at a cumulative deficit for U.S. earnings and profit purposes. In the event the Company is required to repatriate funds from outside of the United States, such repatriation would be subject to local laws, customs, and tax consequences. Determination of the amount of unrecognized deferred tax liability related to these earnings is not practicable.
Financial Instruments	Financial instruments The Company has financial instruments that are measured at fair value. To determine the fair value, the Company uses the fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows: • Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities; • Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and • Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use. Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. As of June 30, 2021, the Company’s milestone payment liability was measured using level 3 inputs (note 3). The Company’s financial instruments consist of cash and cash equivalents, other receivables, accounts payable, and related party payables. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments.
Intangible Assets	Intangible assets Website development costs Website development costs are stated at cost less accumulated amortization. The Company capitalizes website development costs associated with graphics design and development of the website application and infrastructure. Costs related to planning, content input, and website operations are expensed as incurred. The Company amortizes website development costs on a straight-line basis over three years. Patents Expenditures associated with the filing, or maintenance of patents, licensing or technology agreements are expensed as incurred. Costs previously recognized as an expense are not recognized as an asset in subsequent periods. Once the Company has achieved regulatory approval patent costs will be deferred and amortized over the remaining life of the related patent.
Accruals for Research and Development Expenses and Clinical Trials	Accruals for research and development expenses and clinical trials As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants, and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects of the expenses. The Company determines accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the years ended June 30, 2021 and 2020, there were no material adjustments to the Company’s prior period estimates of accrued expenses for clinical trials.
Warrants and Shares Issued For Services	Warrants and shares issued for services The Company has issued equity instruments for services provided by employees and non-employees. The equity instruments are valued at the fair value of the instrument issued.
Stock Options	Stock options The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement of operations over the service period based on a measurement of fair value for each stock-based award. Prior to our adoption of ASU 2018-07, Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting For the years ended June 30, 2021 and 2020, the determination of grant-date fair value for stock option awards was estimated using the Black-Scholes model, which includes variables such as the expected volatility of our share price, the anticipated exercise behavior of its grantee, interest rates, and dividend yields. For years ended June 30, 2021 and 2020, the Company utilized the plain vanilla method to determine the expected life of stock options. These variables are projected based on our historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. The Company recognizes forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.
Loss Per Share	Loss per share Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the years ended June 30, 2021 and 2020 diluted loss per share does not differ from basic loss per share since the effect of the Company’s warrants, stock options, performance stock units, and convertible preferred shares is anti-dilutive. As of June 30, 2021, potential common shares of 6,974 (2020 – 10,309) related to outstanding common stock warrants, 2,100 (2020 – nil) related to outstanding Series C preferred stock warrants, 6,392 (2020 – 1,559) related to stock options, nil (2020 – 162) relating to outstanding Series B convertible preferred shares, and 17,295 (2020 – nil) relating to outstanding Series C convertible preferred shares were excluded from the calculation of net loss per common share.
Segment Information	Segment information The Company identifies its operating segments based on business activities, management responsibility and geographical location. The Company operates within a single
Recent Accounting Pronouncements	Recent accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that are adopted by the Company as of the specified effective date. Not yet adopted Accounting Standards Update (“ASU”) 2020-06 — Debt - Debt with conversion and other options (subtopic 470-20) and derivatives and hedging – contracts in entity’s own equity (subtopic 815-40): accounting for convertible instruments and contracts in an entity’s own equity The amendments in this update are intended to simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. For public business entities that are not smaller reporting companies, the ASU’s amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. For all other entities, the effective date is for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The guidance may be early adopted for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company has not yet evaluated the impact of adoption of this ASU on its consolidated financial statements and related disclosures. ASU 2020-10 — Codification Improvements The amendments in this update remove references to various FASB Concepts Statements, situates all disclosure guidance in the appropriate disclosure section of the Codification, and makes other improvements and technical corrections to the Codification. The amendments in Sections B and C of this amendment are effective for fiscal periods beginning after December 15, 2020, for public business entities. For all other entities, the amendments are effective for fiscal periods beginning after December 15, 2021, and interim periods within fiscal periods beginning after December 15, 2022. The Company has not yet evaluated the impact of adoption of this ASU on its consolidated financial statements and related disclosures. ASU 2021-04 — Earnings Per Share (Topic 260), Debt— Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in this update are intended to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange and that are not within the scope of another FASB Accounting Standards Codification. The amendments in ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted for all entities, including adoption in an interim period. The Company has not yet evaluated the impact of adoption of this ASU on its consolidated financial statements and related disclosures. During the year ended June 30, 2021, other than ASUs 2020-06, 2020-10, and 2021-04, there have been no new, or existing recently issued, accounting pronouncements that are of significance, or potential significance, that impact the Company’s consolidated financial statements.

Merger (Tables)

Merger (Tables)	12 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
Schedule of Consideration Transferred Stockholders, Recognized Identified Assets Acquired and Liabilities Assumed Under Merger	The following summarizes total consideration transferred to the Adgero stockholders under the Merger as well as the assets acquired and liabilities assumed under the Merger: $ (in thousands) Consideration: Common stock 15,328 Warrants 630 Success fee shares 766 16,724 Net assets acquired: Cash (969 ) Other current assets (11 ) Property and equipment (note 5) (175 ) Accounts payable and accrued liabilities 337 Milestone payment liability 188 In-process research and development 16,094
Schedule Of Milestone Payment Liability	The discount rate was based on published rates for corporate bonds and the term was based on an estimate of the planned timing of completion of the respective development achievement that would result in payment of the respective milestones. $ (in thousands) Balance – June 30, 2020 — Addition 188 Change in fair value estimate (6 ) Balance – June 30, 2021 182

Property Equipment and Intang_2

Property Equipment and Intangibles (Tables)	12 Months Ended
	Jun. 30, 2021
Property Plant And Equipment [Abstract]
Schedule of Property Equipment and Intangibles	Property, equipment and intangibles $ (thousands) Balance, June 30, 2019 12 Less amortization (10 ) Balance, June 30, 2020 2 Acquired in Adgero merger (note 3) 175 Laboratory equipment purchased 8 Disposal of furniture (3 ) Property and equipment 182 Less depreciation and amortization (32 ) Balance, June 30, 2021 150

Loan from National Brain Tumo_2

Loan from National Brain Tumor Society and National Foundation for Cancer Research (Tables)	12 Months Ended
	Jun. 30, 2021
Loans Payable [Abstract]
Summary of Loan	$ (in thousands) Balance – June 30, 2020 — Funding 500 Financing costs (94 ) Interest expense 30 Amortization of deferred financing costs 94 Payment of principal and interest (530 ) Balance – June 30, 2021 —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2021
Class Of Stock [Line Items]
Schedule of Stock Option Expense	Years ended June 30, 2021 $ 2020 $ Research and development 1,478 87 General and administrative 3,798 408 5,276 495
Schedule of Unvested Stock Options	Number of options (in thousands) Weighted average exercise price $ Unvested at June 30, 2019 85 11.35 Granted 1,291 0.63 Vested (500 ) 1.87 Forfeited (18 ) 0.61 Unvested at June 30, 2020 858 0.98 Granted 5,074 1.67 Vested (2,058 ) 1.52 Forfeited (14 ) 1.42 Unvested at June 30, 2021 3,860 1.60
Schedule of Warrants	Number of warrants (in thousands) Weighted average exercise price $ Balance – June 30, 2019 1,543 12.60 Underwritten public offering 10,418 0.75 Issuance of 2020 Underwriter Warrants 377 1.15 Exercise of PFW (2,655 ) 0.01 Exercise of 2020 Investor Warrants (25 ) 1.00 Warrants issued for services (i) 655 0.77 Expiry of warrants issued for services (i) (4 ) 59.30 Balance – June 30, 2020 10,309 2.71 Issuance of Adgero Warrants 2,314 3.18 Exercise of warrants (ii) (4,907 ) 1.00 Warrants issued for services (i) 600 1.74 Expiry of warrants (1,342 ) 6.00 Balance – June 30, 2021 6,974 3.34 i) Warrants issued for services are exercisable at various prices and expire at the various dates noted in the table below. ii) A total of 4,404 2020 Investor Warrants were exercised at $1.00 per share and 503 warrants issued as either agent warrants or issued for services were exercised on a cashless basis for which 273 common shares were issued.
Schedule of Changes in Outstanding Warrants	Description of warrants Number (in thousands) Exercise price $ Expiry date 2020 Investor warrants 3,333 1.00 August 16, 2024 2019 Investor warrants 760 3.10 June 5, 2024 2018 Investor warrants 280 12.50 September 22, 2022 2017 Investor warrants 208 35.00 April 19, 2022 NBTS Warrants (i) 125 1.09 June 19, 2025 Warrants issued for services 6 17.80 January 25, 2023 Warrants issued for services 34 11.70 February 27, 2023 Warrants issued for services 12 9.00 September 15, 2023 Warrants issued for services 2 9.00 October 11, 2023 Warrants issued for services 280 0.75 November 18, 2023 Warrants issued for services 125 0.64 January 20, 2024 Warrants issued for services 330 1.49 September 22, 2023 Warrants issued for services 50 1.82 November 13, 2023 Warrants issued for services 100 1.47 January 7, 2024 Warrants issued for services 70 2.75 February 17, 2024 Warrants issued for services 50 2.38 February 25, 2024 2019 Agent warrants 47 3.88 June 3, 2024 2018 Agent warrants 40 12.50 September 20, 2022 2017 Agent warrants 14 40.60 April 12, 2022 Adgero Warrants (ii) 353 3.18 August 31, 2021 Adgero Warrants 755 3.18 January 17, 2022 6,974 (i) NBTS Warrants were issued with respect to loan proceeds received during the year ended June 30, 2021 (note 7). (i i ) Expired unexercised subsequent to June 30, 2021.
Series C Warrants [Member]
Class Of Stock [Line Items]
Schedule of Changes in Outstanding Warrants	Series C Agent Warrants Number Conversion price $ Number of conversion shares (in thousands) Cumulative common stock dividends (in thousands) Series 1 1,929 1.16 1,663 1,164 Series 2 219 1.21 180 126 Series 3 296 1.15 257 180 2,444 2,100 1,470
Schedule of Conversion of Series C Preferred Stock to Series C Warrants	Balance June 30, 2020 Number of Warrants Issued Number of Warrants Exercised Balance, June 30, 2021 Exercise price $ Issuance of Preferred Series C-1 Agent Warrants — 1,959 (30 ) 1,929 1.16 Issuance of Preferred Series C-2 Agent Warrants — 219 — 219 1.21 Issuance of Preferred Series C-3 Agent Warrants — 326 (30 ) 296 1.15 — 2,504 (60 ) 2,444
Stock options [Member]
Class Of Stock [Line Items]
Schedule of Outstanding Under the Legacy Plan	Number of stock options outstanding (in thousands) Weighted average exercise price Balance – June 30, 2019 288 22.31 Granted 1,291 0.63 Forfeited (19 ) 0.61 Expired (1 ) 40.00 Balance – June 30, 2020 1,559 4.61 Granted 5,074 1.67 Exercised (195 ) 0.61 Expired (32 ) 34.88 Forfeited (14 ) 1.42 Balance – June 30, 2021 6,392 2.26
Summary of Stock Options Currently Outstanding and Exercisable	Exercise price $ Number Outstanding at June 30, 2021 (in thousands) Weighted average remaining contractual life (years) Number exercisable at June 30, 2021 (in thousands) 0.61 816 8.18 729 0.74 250 8.37 62 1.36 300 9.23 75 1.37 75 9.83 — 1.70 4,699 9.21 1,415 6.10 25 7.36 24 7.00 3 6.98 3 8.70 12 6.34 12 9.83 83 6.89 83 10.60 4 6.79 4 11.70 30 1.66 30 16.14 3 0.92 3 20.00 9 0.59 9 21.10 11 6.02 11 29.60 5 3.60 5 37.60 5 4.61 5 41.00 4 5.36 4 42.00 30 2.13 30 44.80 3 4.61 3 49.50 13 5.63 13 53.20 8 4.85 8 61.60 1 1.75 1 92.00 3 1.92 3 6,392 2,532
Schedule of Valuation Assumptions Using a Black-Scholes Pricing Model	June 30, 2021 June 30, 2020 Dividend rate — % — % Volatility 103% to 152% 89% to 102% Risk-free rate 0.19% to 1.28% 0.32% to 1.50% Term – years 0.4 to 5.9 4.7 to 5.7
Performance stock units [Member]
Class Of Stock [Line Items]
Schedule of Issuance of Series C Preferred Stock	Series C Preferred Stock Number of shares $ (in thousands) Balance – June 30, 2019 and 2020 — — Issuance 25,028 18,286 Issued on exercise of Series C Agent Warrants 33 79 Conversion of Series C Preferred stock to common stock (4,969 ) (3,713 ) Balance – June 30, 2021 20,092 14,652
Schedule of Series C Preferred Stock Outstanding, Conversion Shares and Future Dividends	Series Number Conversion Price $ Number of conversion shares (in thousands) Dividend Shares (in thousands) Series 1 16,564 1.16 14,279 9,995 Series 2 1,148 1.21 946 662 Series 3 2,380 1.15 2,070 1,449 20,092 17,295 12,106 Series C Dividends Dividend Shares (in thousands) 10% - August 19, 2021 1,729 15% - August 19, 2022 2,594 20% - August 19, 2023 3,459 25% - August 19, 2024 4,324 12,106
Schedule of Conversion of Series B Preferred Stock to Common Stock	Series B Preferred Stock (in thousands) Number of shares $ Balance – June 30, 2019 674 4,699 Conversion of Series B Preferred stock to common stock (25 ) (174 ) Balance – June 30, 2020 649 4,525 Conversion of Series B Preferred stock to common stock (649 ) (4,525 ) Balance – June 30, 2021 — —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Components of Future Tax Assets and Deferred Tax Liabilities	Significant components of the Company’s deferred tax assets and deferred tax liabilities are shown below: June 30, 2021 $ June 30, 2020 $ Deferred tax assets: Non-capital losses carried forward 20,148 11,871 Stock-based compensation 155 — Capital losses carried forward 18 18 Financing costs 326 221 Scientific research and development 761 604 Scientific research and development – Investment Tax Credits (“ITC”) 665 534 22,073 13,248 Deferred tax liabilities: Scientific research and development – ITC (110 ) (88 ) 21,963 13,160 Valuation allowance (21,963 ) (13,160 ) Net future tax assets — —
Schedule of Difference Between Income Tax Rate and Statutory Income Tax Rate	The differences arise from the following items: June 30, 2021 $ June 30, 2020 $ Tax recovery at statutory income tax rates (8,015 ) (1,916 ) Permanent differences 4,506 142 Effect of rate differentials between jurisdictions (551 ) (239 ) Effect of foreign exchange rates (954 ) 347 Non-capital losses acquired with Adgero (4,114 ) — Scientific research and development – ITC 97 (38 ) Adjustment to prior year's provision versus statutory tax returns 228 323 Change in valuation allowance 8,803 1,381 — —

Supplementary Statement of Ca_2

Supplementary Statement of Cash Flows Information (Tables)	12 Months Ended
	Jun. 30, 2021
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplementary Statement of Cash Flows Information	Year ended June 30, 2021 Year ended June 30, 2020 Series B Preferred Stock common stock dividend (note 8) 17 9 Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance (note 8) 3,181 — Non-cash issue costs (note 8) 3,287 182 Deferred costs in accounts payable — 60 Warrants issued as deferred costs (note 7) — 94 Cashless exercise of Series C warrants (note 8) 79 — Conversion of Series B Preferred Stock to common stock (note 8) 4,525 174 Conversion of Series C Preferred Stock to common stock (note 8) 3,713 — Income taxes paid — — Interest paid — —

Financial Risk Management (Tabl

Financial Risk Management (Tables)	12 Months Ended
	Jun. 30, 2021
Risks And Uncertainties [Abstract]
Schedule of Balances in Foreign Currencies	Balances in foreign currencies at June 30, 2021 and 2020 were as follows: June 30, 2021 balances CA$ June 30, 2020 balances CA$ Trade payables 114 167 Cash 30 21 Interest, taxes, and other receivables 11 13
Schedule of Fair Value of Off-Balance Sheet Risks	Cash and cash equivalents $ Insured amount $ Non- insured amount $ 10,537 628 9,909

Nature of Operations, Corpora_2

Nature of Operations, Corporate History, and Going Concern and Management Plans - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Net loss	$ (38,298)	$ (9,126)
Negative cash flow from operations	(18,860)	(7,928)
Cash and cash equivalents	10,537	2,392
Accumulated deficit	(111,225)	$ (69,721)
Proceeds from registered direct financing subsequent	$ 13,600
Substantial Doubt about Companys Ability to Continues Going Concern Period	1 year

Significant Accounting Polici_3

Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2021USD ($)Segmentshares	Jun. 30, 2020shares
Significant Accounting Policies (Textual)
Additional uncertain tax provisions | $	$ 0
Number of operating segments | Segment	1
Number of reportable segments | Segment	1
In-process research and development | $	$ 16,094,000
Property and equipment estimated useful life	three years
Series C Preferred Share Warrants [Member]
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	2,100,000	0
Series B Convertible Preferred Shares [Member]
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	0	162,000
Series C Convertible Preferred Shares [Member]
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	17,295,000	0
Stock options [Member]
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	6,392,000	1,559,000
Warrant [Member]
Significant Accounting Policies (Textual)
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding	6,974,000	10,309,000
Website Development Costs [Member]
Significant Accounting Policies (Textual)
Amortization of website development costs	3 years

Merger - Additional Information

Merger - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended		24 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Legal fee	$ 500	$ 1,054	$ 1,554
Cash or equivalent to common stock	300
Contingent amounts payable to St. Cloud	240		$ 240
Cash paid to employees	$ 60
Merger Agreement [Member]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Stock purchase warrants	2,314
Warrants exercisable price	$ 3.18
Weighted Average Risk Free Interest Rate	0.21%
Weighted Average Remaining Term	1 year
Volatility Rate	115.96%		115.96%
Dividend rate	0.00%
Merger success fee share price	$ 1.34		$ 1.34
Merger Agreement [Member] | Common stock
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Number of shares issued	11,439
Merger Agreement [Member] | Common stock | Private Placement [Member]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Merger success fee	572
REM-001 Therapy [Member]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Cash or equivalent to common stock	$ 700
Contingent amounts payable to St. Cloud	560		$ 560
Cash paid to employees	$ 140

Merger - Schedule of Considerat

Merger - Schedule of Consideration Transferred Stockholders, Recognized Identified Assets Acquired and Liabilities Assumed Under Merger (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2021USD ($)
Consideration:
Common stock	$ 16,724
Cash	(969)
Other current assets	(11)
Property and equipment (note 5)	(175)
Accounts payable and accrued liabilities	337
Milestone payment liability	188
In-process research and development	16,094
Warrant [Member]
Consideration:
Common stock	630
Common stock
Consideration:
Common stock	15,328
Success Fee Shares [Member]
Consideration:
Common stock	$ 766

Merger - Schedule of Milestone

Merger - Schedule of Milestone Payment Liability (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2021USD ($)
Business Combinations [Abstract]
Addition	$ 188
Change in fair value estimate	(6)
Balance – June 30, 2021	$ 182

Clinical Trial Deposit - Additi

Clinical Trial Deposit - Additional Information (Detail) $ in Thousands	12 Months Ended
	Jun. 30, 2021USD ($)
Other Liabilities [Abstract]
Patient enrollment milestones payments	$ 5,430
Deposits payments	2,600
Deposit payment expensed	500
Remainder of Deposits payments anticipated to future invoice	2,100
Deposits payments anticipated in near term	500
Deposits payments anticipated beyond twelve months	$ 1,600

Property Equipment and Intang_3

Property Equipment and Intangibles - Schedule of Property Equipment and Intangibles (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Property Plant And Equipment [Line Items]
Beginning Balance	$ 2	$ 12
Property and equipment, gross	182
Less depreciation and amortization	(32)	(10)
Ending Balance	150	$ 2
Acquired in Adgero Merger [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	175
Laboratory Equipment Purchased [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	8
Disposal of Furniture [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ (3)

Property Equipment and Intang_4

Property Equipment and Intangibles - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Property Plant And Equipment [Abstract]
Capitalized cost	$ 80	$ 80
Amortization expense	$ 2	$ 10

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Jun. 30, 2021	Jun. 30, 2020
Preferred stock, par value		$ 0.001	$ 0.001
Dividend payable		$ 8	$ 8
Related party payables		$ 561	$ 664
Preferred Stock Series A
Preferred Stock, shares issued		279,000	279,000
Preferred stock, rate of dividend	3.00%
Valent Technologies LLC [Member]
Loan payable outstanding amount	$ 279
Aggregate accrued interest	$ 29
Dividend payable		$ 8	$ 8
Valent Technologies LLC [Member] | Preferred Stock Series A
Preferred Stock, shares issued	279
Preferred stock, par value	$ 1

Loan from National Brain Tumo_3

Loan from National Brain Tumor Society and National Foundation for Cancer Research - Summary of Loan (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Guarantee Obligations [Line Items]
Deferred financing costs		$ (25)
Interest expense	$ 30
Amortization of deferred financing costs	94
N B T S and N F C R [Member]
Guarantee Obligations [Line Items]
Funding	500
Deferred financing costs	(94)
Interest expense	30
Amortization of deferred financing costs	94
Payment of principal and interest	$ (530)

Loan from National Brain Tumo_4

Loan from National Brain Tumor Society and National Foundation for Cancer Research - Additional information (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Guarantee Obligations [Line Items]
Warrants exercised for cash	$ 4,404	$ 51
National Brain Tumor Society and National Foundation for Cancer Research [Member]
Guarantee Obligations [Line Items]
Loan received	500
National Brain Tumor Society [Member]
Guarantee Obligations [Line Items]
Repayment of loan	500
Repayment of loan interest	$ 30
National Brain Tumor Society [Member] | Warrant [Member]
Guarantee Obligations [Line Items]
Warrants issued	125
Warrants exercise price	$ 1.09
Warrants exercised for cash	$ 94
Risk-free interest rate	0.37%
Volatility Rate	89.82%
Expected Term	5 years
Dividend Rate	0.00%
National Brain Tumor Society [Member] | Promissory Note [Member]
Guarantee Obligations [Line Items]
Accrued interest rate	6.00%
Debt, maturity date	Jun. 19, 2021

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Issuance of Series C Preferred Stock (Detail) $ in Thousands	12 Months Ended
	Jun. 30, 2021USD ($)shares
Class Of Stock [Line Items]
Conversion of Series C Preferred stock to common stock	$ 3,713
Preferred Stock Series C
Class Of Stock [Line Items]
Issuance	$ 18,286
Issuance, shares | shares	25,028
Issued on exercise of Series C Agent Warrants	$ 79
Issued on exercise of Series C Agent Warrants, shares | shares	33
Conversion of Series C Preferred stock to common stock	$ (3,713)
Conversion of series C preferred stock to common stock, shares | shares	(4,969)
Ending Balance	$ 14,652
Ending Balance, shares | shares	20,092

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	Apr. 29, 2021shares	Aug. 16, 2019USD ($)$ / sharesshares	Sep. 30, 2014$ / sharesshares	Aug. 19, 2021shares	Jun. 26, 2021shares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2016$ / sharesshares	Jun. 25, 2021shares	Jun. 30, 2019shares	Jun. 26, 2019shares
Class Of Stock [Line Items]
Preferred stock, par value | $ / shares						$ 0.001	$ 0.001
Common stock shares authorized						175,000,000	95,000,000
Underwritten Public Offering Description		the Company closed on the sale of (i) 4,895 shares of its common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 2,655 shares of Common Stock and (iii) common warrants to purchase an aggregate of 7,763 shares of Common Stock (“2020 Investor Warrants”), including 800 shares of Common Stock and 2020 Investor Warrants to purchase an aggregate of 1,013 shares of Common Stock sold pursuant to a partial exercise by the underwriters of the underwriters’ option to purchase additional securities, in the Company’s underwritten public offering (the “Offering”). Each share of Common Stock or PFW, as applicable, was sold together with a 2020 Investor Warrant to purchase one share of Common Stock at a combined effective price to the public of $1.00 per share of Common Stock and accompanying 2020 Investor Warrant.
Common stock, shares issued						32,740,000	11,458,000
Warrants exercised for cash | $						$ 4,404,000	$ 51,000
Shares issued for services | $						$ 0	$ 13,000
Number of options granted						5,074	1,291
Total compensation expense | $						$ 5,276,000	$ 495,000
Stock options exercisable						2,532,000
Accelerated vested of stock option						280,000
Accelerated expense | $						$ 53,000
Stock option exercise price | $ / shares						$ 0.61
Number of stock options outstanding						6,392,000
Stock options exercise price | $ / shares						$ 0.61
2017 Omnibus Incentive Plan [Member]
Class Of Stock [Line Items]
Common stock, shares issued						13,000
Common stock, shares outstanding						136
Common stock issued under the 2017 Plan						6,256	6,414
Percentage of fully diluted shares of common stock						8.00%
2017 Omnibus Incentive Plan [Member]
Class Of Stock [Line Items]
Number of options granted				156,000	67,000	223,000
Previous grants during the period						250,000
2017 Omnibus Incentive Plan [Member] | Group Two
Class Of Stock [Line Items]
Stock options exercisable						250,000
Stock options [Member]
Class Of Stock [Line Items]
Number of options granted						5,074,000	1,291,000
Stock option exercise price | $ / shares						$ 0.61
Number of options forfeited						14,000	19,000
Stock options exercised, Shares						195,000
Number of stock options outstanding						6,392,000	1,559,000			288,000
Aggregate intrinsic value of stock options outstanding | $						$ 4,759	$ 80
Aggregate intrinsic value of stock options exercisable | $						2,181	35
Unrecognized compensation expense | $						$ 3,014,000
Unrecognized compensation expense, term						2 years 3 months
Aggregate intrinsic value of unvested stock options | $						$ 2,577	$ 45
Weighted average contractual term						9 years 1 month 28 days	9 years 2 months 8 days
Stock options [Member] | CA$ $20.00 Exercise Price
Class Of Stock [Line Items]
Stock option exercise price | $ / shares						$ 16.14
Number of stock options outstanding						2.5
Stock options exercise price | $ / shares						$ 16.14
Common stock
Class Of Stock [Line Items]
Series B preferred stock dividend, shares						11,000	15,000
Conversion of Series B preferred stock to common stock, shares						162,000	6,000
Common stock shares authorized									175,000,000		95,000,000
Issuance of shares and warrants - net of issue costs, shares		4,895,000					4,895,000
Warrants exercise price | $ / shares		$ 0.001
Shares issued for services, shares						0	23,000
Stock options exercised, Shares						170,000
Pre-Funded Warrants
Class Of Stock [Line Items]
Issuance of shares and warrants - net of issue costs, shares		2,655,000
Warrants exercise price | $ / shares							$ 0.01
Number							2,655,000
Warrants exercised for cash | $							$ 27,000
2020 Investor Warrant [Member]
Class Of Stock [Line Items]
Issuance of shares and warrants - net of issue costs, shares		7,763,000
Common stock, shares issued		800,000
Warrants To Purchase Common Stock		1,013,000
Other Underwriting Expense | $		$ 6,583,000
Expiry date		Aug. 16, 2024
Director | 2017 Omnibus Incentive Plan [Member]
Class Of Stock [Line Items]
Total compensation expense | $						$ 319,000
Director | 2017 Omnibus Incentive Plan [Member] | Minimum
Class Of Stock [Line Items]
Exercise period						90 days
Director | 2017 Omnibus Incentive Plan [Member] | Maximum
Class Of Stock [Line Items]
Exercise period						1 year
Executive Officers and Directors | 2017 Omnibus Incentive Plan [Member]
Class Of Stock [Line Items]
Number of options granted						4,834,000
Number of options expected to vest						4,279,000
Stock option vesting description						Of the total granted, 4,279 options to purchase shares of common stock vest as to 1/6 on the six-month anniversary of the grant date with the remaining portion vesting in equal monthly installments over a period of 30 months commencing on the seven-month anniversary of the grant date, 480 vest in 12 equal monthly installments beginning on October 15, 2020, and 75 vest as to 1/6 on the twelve-month anniversary of the grant date with the remaining portion vesting in equal quarterly installments over a period of eight quarters commencing on the fifteen-month anniversary of the grant date.  All of the options to purchase shares of common stock granted have a 10-year term and are subject to cancellation upon the grantees’ termination of service for the Company, with certain exceptions.
Stock option term						10 years
Executive Officers and Directors | 2017 Omnibus Incentive Plan [Member] | Exercise Price of 1.70
Class Of Stock [Line Items]
Number of options granted						4,699,000
Stock option exercise price | $ / shares						$ 1.70
Executive Officers and Directors | 2017 Omnibus Incentive Plan [Member] | Exercise Price of 1.355
Class Of Stock [Line Items]
Stock option exercise price | $ / shares						$ 1.355
Number of options forfeited						60,000
Executive Officers and Directors | 2017 Omnibus Incentive Plan [Member] | Exercise Price of One Point Three Seven [Member]
Class Of Stock [Line Items]
Stock option exercise price | $ / shares						$ 1.37
Stock options exercised, Shares						75,000
Preferred Stock Series C
Class Of Stock [Line Items]
Shares issued of common stock for services						25,028
Conversion of stock						21,516
Preferred Stock, shares issued						20,000	0
Preferred stock, shares outstanding						20,000	0
Number						20,092,000
Preferred Stock Series C | Placement Agent | Series C Agent Warrants [Member]
Class Of Stock [Line Items]
Stock issued during period shares new issues						2,504
Fair value of preferred stock | $						$ 3,287,000
Series C-1 Preferred Shares [Member]
Class Of Stock [Line Items]
Preferred stock | $ / shares						$ 1.16
Number						16,564,000
Series C-2 Preferred Shares [Member]
Class Of Stock [Line Items]
Preferred stock | $ / shares						$ 1.214
Number						1,148,000
Series C3 Preferred Shares
Class Of Stock [Line Items]
Preferred stock | $ / shares						$ 1.15
Number						2,380,000
Preferred Stock Series B
Class Of Stock [Line Items]
Stock issued during period shares new issues								902
Preferred stock | $ / shares								$ 32
Preferred stock, rate of dividend								9.00%
Purchase price of shares | $ / shares								$ 8
Convertible preferred stock						48	25	0.25
Conversion Of Preferred Stock To Common Stock Date								Apr. 29, 2021
Liquidation value | $							$ 5,189
Conversion of Series B preferred stock to common stock, shares	150,000						162,000
Direct increase in accumulated deficit | $						$ 17,000	$ 9,000
Preferred Stock, shares issued	601,000					0	649,000
Final closing date	5 years
Preferred stock, shares outstanding						0	649,000
Common stock
Class Of Stock [Line Items]
Series B preferred stock dividend, shares						11	15
Conversion of Series B preferred stock to common stock, shares						12	6
Preferred Stock Series A
Class Of Stock [Line Items]
Preferred stock, rate of dividend			3.00%
Liquidation value | $						$ 279,000
Preferred Stock, shares issued						279,000	279,000
Preferred stock, shares outstanding						279,000	279,000
Change in preferred stock | $						$ 0	$ 0
Preferred Stock Series A | Exchange Agreement
Class Of Stock [Line Items]
Preferred stock, rate of dividend			3.00%
Preferred Stock, shares issued			279
Preferred stock, par value | $ / shares			$ 1
Series C Agent Warrants [Member] | Placement Agent
Class Of Stock [Line Items]
Fair value disclosure | $						$ 3,287,000
Warrants outstanding, term						4 years
Series C Agent Warrants [Member] | Placement Agent | Measurement Input, Risk Free Interest Rate
Class Of Stock [Line Items]
Warrants outstanding, measurement input						0.27
Series C Agent Warrants [Member] | Placement Agent | Minimum | Measurement Input, Price Volatility
Class Of Stock [Line Items]
Warrants outstanding, measurement input						95.2
Series C Agent Warrants [Member] | Placement Agent | Maximum | Measurement Input, Price Volatility
Class Of Stock [Line Items]
Warrants outstanding, measurement input						95.8
Private Placement [Member] | Preferred Stock Series C
Class Of Stock [Line Items]
Shares issued of common stock for services						25,028
Proceeds from private placement | $						$ 25,028,000
Net proceeds from private placement | $						21,573,000
Deferred financing costs | $						3,455,000
Cumulative dividends | $						$ 15,062,000
Private Placement [Member] | Series C Preferred Stock Warrants [Member]
Class Of Stock [Line Items]
Shares issued of common stock for services						2,504
Shares issued, price per share | $ / shares						$ 1,000
Series C3 Preferred Shares | Preferred Stock Series C
Class Of Stock [Line Items]
Deferred financing costs | $							$ 85,000
Underwriting Offering | 2020 Investor Warrant [Member]
Class Of Stock [Line Items]
Warrants exercise price | $ / shares		$ 1.15
Expiry date		Aug. 14, 2022
Number		377,000
Warrants And Rights Outstanding Maturity Date		Feb. 10, 2020
Merger Agreement [Member]
Class Of Stock [Line Items]
Dividend rate						0.00%
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C
Class Of Stock [Line Items]
Shares issued of common stock for services						25,028
Shares issued, price per share | $ / shares						$ 1,000
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C | First Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate						10.00%
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C | Second Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate						15.00%
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C | Third Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate						20.00%
Merger Agreement [Member] | Private Placement [Member] | Preferred Stock Series C | Fourth Anniversary [Member]
Class Of Stock [Line Items]
Dividend rate						25.00%

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Series C Preferred Stock Outstanding, Conversion Shares and Future Dividends (Detail) shares in Thousands	12 Months Ended
	Jun. 30, 2021$ / sharesshares
Series C-1 Preferred Shares [Member]
Class Of Stock [Line Items]
Number	16,564
Preferred stock | $ / shares	$ 1.16
Number of conversion shares (in thousands)	14,279
Dividend Shares (in thousands)	9,995
Series C-2 Preferred Shares [Member]
Class Of Stock [Line Items]
Number	1,148
Preferred stock | $ / shares	$ 1.214
Number of conversion shares (in thousands)	946
Dividend Shares (in thousands)	662
Series C3 Preferred Shares
Class Of Stock [Line Items]
Number	2,380
Preferred stock | $ / shares	$ 1.15
Number of conversion shares (in thousands)	2,070
Dividend Shares (in thousands)	1,449
Preferred Stock Series C
Class Of Stock [Line Items]
Number	20,092
Number of conversion shares (in thousands)	17,295
Dividend Shares (in thousands)	12,106
Preferred Stock Series C | 10% - August 19, 2021 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	1,729
Preferred Stock Series C | 15% - August 19, 2022 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	2,594
Preferred Stock Series C | 20% - August 19, 2023 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	3,459
Preferred Stock Series C | 25% - August 19, 2024 [Member]
Class Of Stock [Line Items]
Dividend Shares (in thousands)	4,324

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Conversion of Series B Preferred Stock to Common Stock (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Class of Stock [Line Items]
Beginning Balance	$ 263	$ 1,968
Ending Balance	10,581	263
Preferred Stock Series B
Class of Stock [Line Items]
Beginning Balance	4,525	4,699
Conversion of Series B Preferred stock to common stock	$ (4,525)	(174)
Ending Balance		$ 4,525
Beginning Balance, shares	649,000	674,000
Conversion of Series B Preferred stock to common stock, shares	(649,000)	(25,000)
Ending Balance, shares		649,000

Stockholders' Equity - Schedu_4

Stockholders' Equity - Schedule of Outstanding Under the Legacy Plan (Detail) - $ / shares	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Class of Stock [Line Items]
Beginning balance
Granted	5,074	1,291
Ending balance	6,392,000
Stock options [Member]
Class of Stock [Line Items]
Beginning balance	1,559,000	288,000
Granted	5,074,000	1,291,000
Exercised	(195,000)
Forfeited	(14,000)	(19,000)
Expired	(32,000)	(1,000)
Ending balance	6,392,000	1,559,000
Beginning balance	$ 4.61	$ 22.31
Granted	1.67	0.63
Exercised	0.61
Forfeited	1.42	0.61
Expired	34.88	40
Ending balance	$ 2.26	$ 4.61

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Options Outstanding and Exercisable (Detail)	12 Months Ended
	Jun. 30, 2021$ / sharesshares
Class of Stock [Line Items]
Number of stock options outstanding	6,392,000
Stock options exercisable	2,532,000
Exercise Price One [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 0.61
Number of stock options outstanding	816,000
Weighted average remaining contractual life (years)	8 years 2 months 4 days
Stock options exercisable	729,000
Exercise Price Two [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 0.74
Number of stock options outstanding	250,000
Weighted average remaining contractual life (years)	8 years 4 months 13 days
Stock options exercisable	62,000
Exercise Price Three [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 1.36
Number of stock options outstanding	300,000
Weighted average remaining contractual life (years)	9 years 2 months 23 days
Stock options exercisable	75,000
Exercise Price Four [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 1.37
Number of stock options outstanding	75,000
Weighted average remaining contractual life (years)	9 years 9 months 29 days
Exercise Price Five [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 1.70
Number of stock options outstanding	4,699,000
Weighted average remaining contractual life (years)	9 years 2 months 15 days
Stock options exercisable	1,415,000
Exercise Price Six [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 6.10
Number of stock options outstanding	25,000
Weighted average remaining contractual life (years)	7 years 4 months 9 days
Stock options exercisable	24,000
Exercise Price Seven [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 7
Number of stock options outstanding	3,000
Weighted average remaining contractual life (years)	6 years 11 months 23 days
Stock options exercisable	3,000
Exercise Price Eight [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 8.70
Number of stock options outstanding	12,000
Weighted average remaining contractual life (years)	6 years 4 months 2 days
Stock options exercisable	12,000
Exercise Price Nine [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 9.83
Number of stock options outstanding	83,000
Weighted average remaining contractual life (years)	6 years 10 months 20 days
Stock options exercisable	83,000
Exercise Price Ten [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 10.60
Number of stock options outstanding	4,000
Weighted average remaining contractual life (years)	6 years 9 months 14 days
Stock options exercisable	4,000
Exercise Price Eleven [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 11.70
Number of stock options outstanding	30,000
Weighted average remaining contractual life (years)	1 year 7 months 28 days
Stock options exercisable	30,000
Exercise Price Twelve [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 16.14
Number of stock options outstanding	3,000
Weighted average remaining contractual life (years)	11 months 1 day
Stock options exercisable	3,000
Exercise Price Thirteen [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 20
Number of stock options outstanding	9,000
Weighted average remaining contractual life (years)	7 months 2 days
Stock options exercisable	9,000
Exercise Price Fourteen [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 21.10
Number of stock options outstanding	11,000
Weighted average remaining contractual life (years)	6 years 7 days
Stock options exercisable	11,000
Exercise Price Fifteen [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 29.60
Number of stock options outstanding	5,000
Weighted average remaining contractual life (years)	3 years 7 months 6 days
Stock options exercisable	5,000
Exercise Price Sixteen [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 37.60
Number of stock options outstanding	5,000
Weighted average remaining contractual life (years)	4 years 7 months 9 days
Stock options exercisable	5,000
Exercise Price Seventeen [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 41
Number of stock options outstanding	4,000
Weighted average remaining contractual life (years)	5 years 4 months 9 days
Stock options exercisable	4,000
Exercise Price Eighteen [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 42
Number of stock options outstanding	30,000
Weighted average remaining contractual life (years)	2 years 1 month 17 days
Stock options exercisable	30,000
Exercise Price Nineteen [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 44.80
Number of stock options outstanding	3,000
Weighted average remaining contractual life (years)	4 years 7 months 9 days
Stock options exercisable	3,000
Exercise Price Twenty [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 49.50
Number of stock options outstanding	13,000
Weighted average remaining contractual life (years)	5 years 7 months 17 days
Stock options exercisable	13,000
Exercise Price Twenty One [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 53.20
Number of stock options outstanding	8,000
Weighted average remaining contractual life (years)	4 years 10 months 6 days
Stock options exercisable	8,000
Exercise Price Twenty Two [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 61.60
Number of stock options outstanding	1,000
Weighted average remaining contractual life (years)	1 year 9 months
Stock options exercisable	1,000
Exercise Price Twenty Three [Member]
Class of Stock [Line Items]
Exercise price | $ / shares	$ 92
Number of stock options outstanding	3,000
Weighted average remaining contractual life (years)	1 year 11 months 1 day
Stock options exercisable	3,000

Stockholders' Equity - Schedu_5

Stockholders' Equity - Schedule of Valuation Assumptions Using a Black-Scholes Pricing Model (Detail) - Stock options [Member]	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Minimum
Class of Stock [Line Items]
Volatility Rate	103.00%	89.00%
Risk-free interest rate	0.19%	0.32%
Expected Term	4 months 24 days	4 years 8 months 12 days
Maximum
Class of Stock [Line Items]
Volatility Rate	152.00%	102.00%
Risk-free interest rate	1.28%	1.50%
Expected Term	5 years 10 months 24 days	5 years 8 months 12 days

Stockholders' Equity - Schedu_6

Stockholders' Equity - Schedule of Stock Option Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Class of Stock [Line Items]
Total compensation expense	$ 5,276	$ 495
Research and Development [Member]
Class of Stock [Line Items]
Total compensation expense	1,478	87
General and Administrative [Member]
Class of Stock [Line Items]
Total compensation expense	$ 3,798	$ 408

Stockholders' Equity - Schedu_7

Stockholders' Equity - Schedule of Unvested Stock Options (Detail) - $ / shares	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Equity [Abstract]
Beginning balance	858	85
Granted	5,074	1,291
Vested	(2,058)	(500)
Forfeited	(14)	(18)
Ending balance	3,860	858
Beginning balance	$ 0.98	$ 11.35
Granted	1.67	0.63
Vested	1.52	1.87
Weighted average exercise price unvested, Forfeited	1.42	0.61
Ending balance	$ 1.60	$ 0.98

Stockholders' Equity - Schedu_8

Stockholders' Equity - Schedule of Warrants (Detail) - Warrant [Member] - $ / shares		12 Months Ended
		Jun. 30, 2021		Jun. 30, 2020
Balance – June 30, 2019		10,309,000		1,543,000
Underwritten public offering				10,418,000
Issuance of 2020 Underwriter Warrants				377,000
Exercise of PFW				(2,655,000)
Issuance of Adgero Warrants		2,314,000
Exercise of 2020 Investor Warrants				(25,000)
Warrants issued for services	[1]	600,000		655,000
Expiry of warrants issued for services	[1]			(4,000)
Balance – June 30, 2020		6,974,000		10,309,000
Exercise of warrants	[2]	(4,907,000)
Expiry of warrants		(1,342,000)
Beginning balance		$ 2.71		$ 12.60
Underwritten public offering				0.75
Issuance of 2020 Underwriter Warrants				1.15
Exercise of PFW				0.01
Issuance of Adgero Warrants		3.18
Stock option exercise price		1	[2]	1
Warrants issued for services	[1]	1.74		0.77
Expired		6
Expiry of warrants issued for services	[1]			59.30
Ending balance		$ 3.34		$ 2.71
[1]	Warrants issued for services are exercisable at various prices and expire at the various dates noted in the table below.
[2]	A total of 4,404 2020 Investor Warrants were exercised at $1.00 per share and 503 warrants issued as either agent warrants or issued for services were exercised on a cashless basis for which 273 common shares were issued.

Stockholders' Equity - Schedu_9

Stockholders' Equity - Schedule of Warrants (Parenthetical) (Detail) - 2020 Investor Warrant [Member]	12 Months Ended
	Jun. 30, 2021$ / sharesshares
Investor warrants exercised	4,404,000
Warrants exercise price | $ / shares	$ 1
Exercise of warrants for cash, shares	503,000
Number of common shares called by warrants exercise	273,000

Stockholders' Equity - Sched_10

Stockholders' Equity - Schedule of Outstanding Warrants (Detail) - Warrant [Member]	12 Months Ended
	Jun. 30, 2021$ / sharesshares
Number	6,974,000
Issued For Services One [Member]
Number	6,000
Warrants exercise price | $ / shares	$ 17.80
Expiry date	Jan. 25, 2023
Issued For Services Two [Member]
Number	34,000
Warrants exercise price | $ / shares	$ 11.70
Expiry date	Feb. 27, 2023
Issued For Services Three [Member]
Number	12,000
Warrants exercise price | $ / shares	$ 9
Expiry date	Sep. 15, 2023
Issued For Services Four [Member]
Number	2,000
Warrants exercise price | $ / shares	$ 9
Expiry date	Oct. 11, 2023
Issued For Services Five [Member]
Number	280,000
Warrants exercise price | $ / shares	$ 0.75
Expiry date	Nov. 18, 2023
Issued For Services Six [Member]
Number	125,000
Warrants exercise price | $ / shares	$ 0.64
Expiry date	Jan. 20, 2024
Issued For Services Seven [Member]
Number	330,000
Warrants exercise price | $ / shares	$ 1.49
Expiry date	Sep. 22, 2023
Issued For Services Eight [Member]
Number	50,000
Warrants exercise price | $ / shares	$ 1.82
Expiry date	Nov. 13, 2023
Issued For Services Nine [Member]
Number	100,000
Warrants exercise price | $ / shares	$ 1.47
Expiry date	Jan. 7, 2024
Issued For Services Ten [Member]
Number	70,000
Warrants exercise price | $ / shares	$ 2.75
Expiry date	Feb. 17, 2024
Issued For Services Eleven [Member]
Number	50,000
Warrants exercise price | $ / shares	$ 2.38
Expiry date	Feb. 25, 2024
Investor One [Member]
Number	3,333,000
Warrants exercise price | $ / shares	$ 1
Expiry date	Aug. 16, 2024
InvestorTwo [Member]
Number	760,000
Warrants exercise price | $ / shares	$ 3.10
Expiry date	Jun. 5, 2024
InvestorThree [Member]
Number	280,000
Warrants exercise price | $ / shares	$ 12.50
Expiry date	Sep. 22, 2022
Investor Four
Number	208,000
Warrants exercise price | $ / shares	$ 35
Expiry date	Apr. 19, 2022
NBTS [Member]
Number	125,000	[1]
Warrants exercise price | $ / shares	$ 1.09	[1]
Expiry date	Jun. 19, 2025	[1]
Agent [Member]
Number	47,000
Warrants exercise price | $ / shares	$ 3.88
Expiry date	Jun. 3, 2024
Agent One [Member]
Number	40,000
Warrants exercise price | $ / shares	$ 12.50
Expiry date	Sep. 20, 2022
Agent Two [Member]
Number	14,000
Warrants exercise price | $ / shares	$ 40.60
Expiry date	Apr. 12, 2022
Adgero Warrants One
Number	353,000	[2]
Warrants exercise price | $ / shares	$ 3.18	[2]
Expiry date	Aug. 31, 2021	[2]
Adgero Warrants Two
Number	755,000
Warrants exercise price | $ / shares	$ 3.18
Expiry date	Jan. 17, 2022
[1]	NBTS Warrants were issued with respect to loan proceeds received during the year ended June 30, 2021 (note 7).
[2]	Expired unexercised subsequent to June 30, 2021.

Stockholders' Equity - Sched_11

Stockholders' Equity - Schedule of Outstanding Series C Preferred Stock Warrants (Detail) - Series C Warrants [Member]	12 Months Ended
	Jun. 30, 2021warrant$ / sharesshares
Number of Warrants Issued | warrant	2,504
Number of Warrants Exercised	(60)
Balance	2,444
Issuance of Preferred Series C-1 Agent Warrants [Member]
Number of Warrants Issued | warrant	1,959
Number of Warrants Exercised	(30)
Balance	1,929
Warrants exercise price | $ / shares	$ 1.16
Issuance of Preferred Series C-2 Agent Warrants [Member]
Number of Warrants Issued | warrant	219
Balance	219
Warrants exercise price | $ / shares	$ 1.21
Issuance of Preferred Series C-3 Agent Warrants [Member]
Number of Warrants Issued | warrant	326
Number of Warrants Exercised	(30)
Balance	296
Warrants exercise price | $ / shares	$ 1.15

Stockholders' Equity - Sched_12

Stockholders' Equity - Schedule of Outstanding Series C Agent Warrants (Detail) - Series C Warrants [Member]	12 Months Ended
	Jun. 30, 2021$ / sharesshares
Number	2,444
Number of conversion shares (in thousands)	2,100,000
Cumulative common stock dividends (in thousands)	1,470,000
Series 1 Warrants Outstanding
Number	1,929
Warrants exercise price | $ / shares	$ 1.16
Number of conversion shares (in thousands)	1,663,000
Cumulative common stock dividends (in thousands)	1,164,000
Series 2 Warrants Outstanding Member
Number	219
Warrants exercise price | $ / shares	$ 1.21
Number of conversion shares (in thousands)	180,000
Cumulative common stock dividends (in thousands)	126,000
Series 3 Warrants Outstanding
Number	296
Warrants exercise price | $ / shares	$ 1.15
Number of conversion shares (in thousands)	257,000
Cumulative common stock dividends (in thousands)	180,000

Income Taxes - Components of de

Income Taxes - Components of deferred Tax Assets and Deferred Tax Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020
Deferred tax assets:
Non-capital losses carried forward	$ 20,148	$ 11,871
Stock-based compensation	155
Capital losses carried forward	18	18
Financing costs	326	221
Scientific research and development	761	604
Scientific research and development – Investment Tax Credits (“ITC”)	665	534
Deferred tax assets	22,073	13,248
Deferred tax liabilities:
Scientific research and development – ITC	(110)	(88)
Gross future tax assets	21,963	13,160
Valuation allowance	(21,963)	(13,160)
Net future tax assets

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Current and Future Income Taxes (Textual)
Statutory income tax rate	21.00%	21.00%
Deferred tax assets, Operating loss carryforwards, Not subject to expiration	$ 20,400
Percentage of taxable income, limitation on NOLs	80.00%
Investment tax credits expire, description	expire between 2031 and 2040
Current income tax expense (benefit)	$ 0
Open tax years	2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Represents minimum cumulative percentage of change in ownership as a condition to offset taxable income or tax	50.00%
Cumulative change in ownership period	3 years
United States [Member]
Current and Future Income Taxes (Textual)
Loss before income taxes	$ 29,000
Operating loss carryforwards	$ 15,800
Net operating loss expire, description	begin expiring in 2026
US and Canadian [Member]
Current and Future Income Taxes (Textual)
Operating loss carryforwards	$ 77,700	$ 47,800
Canadian [Member]
Current and Future Income Taxes (Textual)
Loss before income taxes	9,200
Operating loss carryforwards	$ 41,500
Net operating loss expire, description	begin expiring in 2030
Non-refundable federal investment tax credits	$ 407	329
British Columbia [Member]
Current and Future Income Taxes (Textual)
Non-refundable federal investment tax credits	$ 258	205
Investment tax credits expire, description	expire between 2021 and 2030
Canadian Scientific Research and Development [Member]
Current and Future Income Taxes (Textual)
Non-refundable federal investment tax credits	$ 2,800	$ 2,200

Income Taxes - Schedule of Diff

Income Taxes - Schedule of Difference Between Income Tax Rate and Statutory Income Tax Rate (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Effective income tax rate differs from the statutory income tax rate
Tax recovery at statutory income tax rates	$ (8,015)	$ (1,916)
Permanent differences	4,506	142
Effect of rate differentials between jurisdictions	(551)	(239)
Effect of foreign exchange rates	(954)	347
Non-capital losses acquired with Adgero	(4,114)
Scientific research and development – ITC	97	(38)
Adjustment to prior year's provision versus statutory tax returns	228	323
Change in valuation allowance	8,803	1,381
Income tax expense benefit

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2021CAD ($)	Jun. 30, 2020USD ($)
Commitments and Contingencies (Textual)
Manufacturing and clinical study management related cost	$ 10,049,000
Deposits related to study initiation	2,310,000
Rent expense	$ 40,000		$ 40,000
Head Office [Member]
Commitments and Contingencies (Textual)
Lease rent for office space term	1 year	1 year
Lease rent for office space	$ 2,300
Administrative Offices [Member]
Commitments and Contingencies (Textual)
Lease rent for office space	$ 3,500
CAD [Member] | Administrative Offices [Member]
Commitments and Contingencies (Textual)
Lease rent for office space		$ 4,400

Supplementary Statement of Ca_3

Supplementary Statement of Cash Flows Information - Schedule of Supplementary Statement of Cash Flows Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Supplemental Cash Flow Information [Abstract]
Series B Preferred Stock common stock dividend (note 8)	$ 17	$ 9
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance (note 8)	3,181
Non-cash issue costs (note 8)	3,287	182
Deferred costs in accounts payable		60
Warrants issued as deferred costs (note 7)		94
Conversion of Series B Preferred Stock to common stock (note 8)	4,525	174
Conversion of Series C Preferred Stock to common stock (note 8)	3,713
Income taxes paid
Interest paid
Series C Warrants [Member]
Supplemental Cash Flow Information [Abstract]
Cashless exercise of warrants	$ 79

Financial Risk Management - Add

Financial Risk Management - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Foreign Currency Fair Value Hedge Derivative [Line Items]
Cash and cash equivalents	$ 10,537	$ 2,392
Credit risk, financial instrument maximum exposure	8
Credit risk, uninsured cash and cash equivalents	9,909
Liquidity Risk [Member]
Foreign Currency Fair Value Hedge Derivative [Line Items]
Liquidity risk maximum exposure	2,962
Foreign exchange risk [Member]
Foreign Currency Fair Value Hedge Derivative [Line Items]
Financial risk, accounts payable and accrued liabilities	$ 59
Maximum exposure of financial currency due to exchange rates, description	Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. If foreign exchange rates were to fluctuate within +/-10% of the closing rate at year-end, the maximum exposure is $10.
Foreign exchange risk maximum exposure	$ 10
Cash and cash equivalents	$ 10,537
Maximum exposure of interest rate risk, description	The Company’s cash balance currently earns interest at standard bank rates. If interest rates were to fluctuate within +/-10% of the closing rate at year end the impact of the Company’s interest-bearing accounts will be not be significant due to the current low market interest rates.

Financial Risk Management - Sch

Financial Risk Management - Schedule of Balances in Foreign Currencies (Detail) - Foreign exchange risk [Member] - CAD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020
Foreign Currency Fair Value Hedge Derivative [Line Items]
Trade payables	$ 114	$ 167
Cash	30	21
Interest, taxes, and other receivables	$ 11	$ 13

Financial Risk Management - S_2

Financial Risk Management - Schedule of Fair Value of Off-Balance Sheet Risks (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Jun. 30, 2020
Risks And Uncertainties [Abstract]
Cash and cash equivalents	$ 10,537	$ 2,392
Insured amount $	628
Non- insured amount $	$ 9,909

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	Sep. 24, 2021	Aug. 19, 2021	Jul. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Aug. 16, 2019
Subsequent Event [Line Items]
Common stock, shares issued				32,740,000	11,458,000
Number of options granted				5,074	1,291
Stock option exercise price				$ 0.61
Common stock
Subsequent Event [Line Items]
Warrants exercise price						$ 0.001
Conversion of Series C preferred stock to common stock, shares				4,251,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Gross proceeds	$ 15
Common stock, shares issued	7,200,000
Warrants To Purchase Common Stock	12,000,000
Warrants exercise price	$ 1.25		$ 1
Investor warrants exercisable period, description	three and one half years from the date of issuance
Number of warrants exercised			69
Warrants issued			353
Warrants exercise price expired			$ 3.18
Subsequent Event [Member] | Stock Option [Member]
Subsequent Event [Line Items]
Number of options granted			435
Stock option exercise price			$ 1.24
Stock option exercise period			Sep. 22, 2031
Stock option commencing date, Description			The options vest in 12 equal monthly installments commencing October 22, 2021
Subsequent Event [Member] | Preferred Stock Series C
Subsequent Event [Line Items]
Common stock, shares issued		1,698
Dividend rate		10.00%
Subsequent Event [Member] | Series C-1 Preferred Shares [Member]
Subsequent Event [Line Items]
Conversion of Series C preferred stock to common stock, shares			1,125
Subsequent Event [Member] | Series C-1 Preferred Shares [Member] | Common stock
Subsequent Event [Line Items]
Conversion of Series C preferred stock to common stock, shares			970
Subsequent Event [Member] | Series C-2 Preferred Shares [Member]
Subsequent Event [Line Items]
Conversion of Series C preferred stock to common stock, shares			250
Subsequent Event [Member] | Series C-2 Preferred Shares [Member] | Common stock
Subsequent Event [Line Items]
Conversion of Series C preferred stock to common stock, shares			206
Subsequent Event [Member] | Series C3 Preferred Shares
Subsequent Event [Line Items]
Conversion of Series C preferred stock to common stock, shares			335
Subsequent Event [Member] | Series C3 Preferred Shares | Common stock
Subsequent Event [Line Items]
Conversion of Series C preferred stock to common stock, shares			291
Subsequent Event [Member] | Pre-Funded Warrants
Subsequent Event [Line Items]
Common stock, shares issued	4,800,000
Warrants exercise price	$ 0.001
Subsequent Event [Member] | Warrant [Member]
Subsequent Event [Line Items]
Warrants exercise price	$ 1.25
Subsequent Event [Member] | Agent Warrant [Member]
Subsequent Event [Line Items]
Common stock, shares issued	600,000
Warrants exercise price	$ 1.5625
Subsequent Event [Member] | Series C Agent Warrants [Member]
Subsequent Event [Line Items]
Common stock shares accrued		210
Subsequent Event [Member] | Series C Agent Warrants [Member] | Preferred Stock Series C
Subsequent Event [Line Items]
Preferred stock, rate of dividend		10.00%
Dividends payable		0.00%